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Radiation therapy is an important cancer treatment method. Radiation therapy techniques 
have advanced rapidly during last decades. Implementation of intensity modulated treatments 
with modern image guidance has enabled conformal dose distributions and high geometrical ac-
curacy. Stereotactic radiation therapies are high precision treatments with high radiation doses 
for small targets. The accuracy requirements are highlighted in stereotactic treatments and quality 
assurance of treatment plans is an important procedure.  
The aim of this thesis was to quantitatively compare the performance of different commercial 
quality assurance systems for quality assurance (QA) of stereotactic treatment plans with volu-
metric modulated arc therapy technique using flattening filter free (FFF) beams (6 MV FFF or 10 
MV FFF). 48 clinical treatment plans (20 brain, 19 lung and 9 prostate tumors) were verified using 
a portal dosimetry system and a 2D array detector. The portal dosimetry measurements were 
acquired with Varian aS1200 electronic portal imaging device. The 2D array detector was IBA 
I’mRT MatriXX Evolution. Gamma index analysis was performed with gamma criteria of 3% dose 
difference and 3 mm distance to agreement (3%/3 mm), 2%/2 mm, 1%/1 mm and 3%/1 mm. 
Average percentual dose difference was also evaluated from portal dosimetry measurements. 
Energy dependency was investigated comparing results from treatment plans with 6 MV FFF and 
10 MV FFF beams. Effect of analysis threshold was examined with threshold values of 5% and 
60% from the maximum dose. Portal dosimetry for treatment plans with 6 MV FFF beams was 
carried out with two different portal dose prediction algorithms (Varian Portal Dose Image Predic-
tion PDIP and Anisotropic Analytical Algorithm AAA). 
The results show that as the target volume increases, the gamma passing rates increase in 
portal dosimetry measurements for brain and lung tumors. I’mRT MatriXX Evolution measurement 
results show significant target volume dependency, gamma passing rates increasing as the vol-
ume increases in all the target site groups.     
PDIP and I’mRT Matrixx Evolution measurement results show energy dependency (6 MV FFF 
vs. 10 MV FFF). PDIP measurements result in higher gamma passing rates for treatment plans 
with 6 MV FFF than 10 MV FFF. I’mRT MatriXX Evolution measurements result in higher gamma 
passing rates with 10 MV FFF than 6 MV FFF. The analysis threshold value affects the results in 
varying amount depending on the measurement setup, indicating the importance of preselected 
threshold in QA protocols. 
Portal dosimetry measurements with PDIP-algorithm result in higher gamma passing rates 
than measurements with AAA-algorithm. Comparison of portal dosimetry with both algorithm and 
array detector measurements with I’mRT MatriXX Evolution show that the measurement method 
has a significant effect on measurement results. The gamma passing rates decrease and the 
deviations increase from PDIP to AAA and AAA to I’mRT MatriXX Evolution. PDIP results corre-
late with AAA results, but I’mRT MatriXX Evolution results do not correlate with portal dosimetry 
results.  
In conclusion, the QA results of stereotactic treatment plans are dependent on the measure-
ment system, beam energy, target volume and analysis parameters. The QA results obtained 
with different measurement systems cannot be compared directly. This thesis gives quantitative 
information for Varian portal dosimetry and IBA I’mRT MatriXX Evolution -array detector.   
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Sädehoito on tärkeä syövän hoitomuoto. Sädehoitotekniikat ovat kehittyneet nopeasti 
viimeisten vuosikymmenien aikana. Intensiteetti muokatun sädehoidon käyttöönotto yhdessä 
nykyaikaisten kuvantaohjaustekniikoiden kanssa ovat mahdollistaneet konformaaliset 
annosjakaumat sekä korkean geometrisen tarkkuuden. Stereotaktiset sädehoidot ovat korkean 
tarkkuuden hoitoja suurilla sädeannoksilla pieniin kohteisiin. Tarkkuusvaatimukset korostuvat 
stereotaktisissa hoidoissa ja potilassuunnitelmien laadunvarmistus on tärkeä työvaihe. 
Tämän tutkimuksen tarkoitus oli verrata kvantitatiivisesti eri kaupallisten mittalaitteiden 
suorituskykyä stereotaktisten potilassuunnitelmien laadunvarmistuksessa. Potilassuunnitelmat 
on toteutettu kaarihoitotekniikalla hyödyntäen tasoittamattomia säteilykeiloja (6 MV FFF ja 10MV 
FFF). 48 kliinistä potilassuunnitelmaa (20 aivokasvainta, 19 keuhkokasvainta ja 9 eturauhasen 
kasvainta) verifioitiin käyttämällä portaalidosimetriaa sekä 2D tasoilmaisinta. Portaalidosimetria 
toteutettiin Varianin aS1200-ilmaisimella ja tasoilmaisimena käytettiin IBA:n I’mRT MatriXX 
Evolution –tasoilmaisinta. Gamma indeksi analyysi toteutettiin gamma kriteereillä 3% annosero 
ja 3 mm etäisyys ero (3%/3 mm), 2%/2 mm, 1%/1 mm and 3%/1 mm. Portaalidosimetriatuloksista 
määritettiin myös keskimääräinen prosentuaalinen annosero. Energian vaikutusta tutkittiin 
vertaamalla tuloksia suunnitelmista jotka on toteutettu energioilla 6 MV FFF tai 10 MV FFF. 
Analyysikynnyksen vaikutusta tutkittiin vertaamalla kahdella eri kynnyksellä (5% ja 60%) saatuja 
tuloksia. 6 MV FFF-energialla toteutetut potilassuunnitelmat lasketettiin kahdella eri 
portaalidosimetria algoritmilla, Varianin Portal Dose Image Prediction (PDIP)-algoritmilla, sekä 
Anisotropic Analytical (AAA)-algoritmilla. 
Portaalidosimetriatulokset osoittavat, että kohteen kasvaessa, gamma-analyysin 
hyväksymisprosentit kasvavat aivo- ja keuhkokasvainten osalta. I’mRT MatiXX Evolution – 
ilmaisimella gamma-analyysin hyväksymisprosentit kasvavat ja hajonta pienenee kaikkien 
kasvainryhmien välillä kun kohteen koko kasvaa.  
Energiariippuvuus osoitettiin sekä PDIP-portaalidosimetrialla, että I’mRT Matrixx Evolution –
mittauksissa. Portaalidosimetrialla gamma-analyysin hyväksymisprosentit huononevat kun 
käytetään 10 MV FFF-energiaa, verrattuna 6MV FFF-energiaan. I’mRT MatriXX Evolution –
tasoilmaisimella hyväksymisprosentit kasvavat kun käytetään 10 MV FFF-energiaa. 
Analyysikynnys vaikuttaa tuloksiin vaihtelevalla tavalla riippuen mittausasetelmasta, osoittaen 
etukäteen valitun analyysikynnyksen tärkeyttä laadunvarmistusprotokollassa.  
Portaalidosimetria PDIP-algoritmilla antaa korkeampia hyväksymisprosentteja kuin AAA-
algoritmilla. Kun portaalidosimetriaa verrataan tasoilmaisimeen, havaitaan että 
mittausmenetelmä vaikuttaa tuloksiin merkitsevästi. AAA-algoritmilla saadut hyväksymisprosentit 
ovat huonompia kuin PDIP-algoritmilla saadut ja tasoilmaisimella saadut hyväksymisprosentit 
ovat edelleen huonompia ja hajonta suurempaa kuin AAA-algoritmilla. Portaalidosimetriatulokset 
eri algoritmeilla korreloivat keskenään, mutta tasoilmaisimella saadut tulokset eivät korreloi 
portaalidosimetriatulosten kanssa.    
Yhteenvetona voidaan todeta, että stereotaktisten potilassuunnitelmien 
laadunvalvontatulokset riippuvat mittaussysteemistä, käytetystä energiasta, kohteen koosta sekä 
analyysiparametreista. Eri mittalaitteilla saatuja mittaustuloksia ei voida suoraan verrata toisiinsa. 
Tämä työ antaa kvantitatiivista informaatiota Varianin portaalidosimetriasta sekä IBAn I’mRT 
Matrixx EVolution –tasoilmaisimesta.       
 
 
Avainsanat: portaalidosimetria, potilassuunnitelmien laadunvarmistus, stereotaktinen 
sädehoito, aS1200, I’mRT MatriXX Evolution, PDIP, AAA, FFF, VMAT 
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1. INTRODUCTION 
Radiation therapy is an important treatment method in cancer treatments. Radiation ther-
apy techniques have advanced rapidly during last decades. Implementation of intensity 
modulated treatments with modern image guidance has enabled high geometrical accu-
racy and conformal dose distribution in the target while sparing the surrounding tissues 
from high radiation doses. (1) Stereotactic radiation therapy treatments are characterized 
by small target volumes treated into high biologically effective doses by a single dose or 
a few fractionated doses.  Steep dose gradient in stereotactic treatments, together with 
the small target size and high radiation dose, set high requirements for geometrical ac-
curacy and quality assurance (QA) of the treatment plans. (2) The use of flattening filter 
free (FFF) beams enable the use of high dose rates resulting in the reduction of treatment 
times. The importance of reduced treatment time in stereotactic treatments is highlighted, 
due to the high fraction doses and uncomfortable patient immobilization often required 
for stereotactic treatments.  
In daily practice of treatment plan QA, the effortlessness and speed of QA procedures 
are important factors. Sufficient spatial resolution and online measurements are re-
quired. Electronic portal imaging devices (EPID) and array detectors are easy to use 
measurement devices capable of online measurements. The QA of treatment plans is 
based on the comparison of measured and predicted dose distributions. (3) The dose 
distribution analysis is commonly performed with gamma index method (4). The use of 
gamma index method requires determination of analysis parameters used: dose devia-
tion, distance-to-agreement, pixels to be analyzed and gamma pass rate criterion.  Var-
ian (Varian Medical Systems, Palo Alto, CA) offers an EPID capable of measuring FFF-
beams with high dose rate without saturation and two different algorithms (Portal Dose 
Image Prediction (PDIP) and Anisotropic Analytical Algorithm (AAA)) for portal dose cal-
culation for 6 MV FFF (6 FFF) beams. (5) 
The aim of this thesis was to determine the current status of QA of stereotactic treatment 
plans with FFF-beams and to investigate the performance of Varian aS1200-EPID and 
I’mRT MatriXX Evolution (IBA Dosimetry GmbH, Schrwarzenbruck, Germany)  –array 
detector in stereotactic treatment plans with FFF-beams. Only a few scientific publica-
tions (6, 7) presenting comparisons of QA measurement devices for stereotactic treat-
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ment plans with FFF-beams were found in the literature. Scientific publications compar-
ing portal dosimetry with Varian aS1200-EPID and I’mRT MatriXX Evolution array detec-
tor were not found. Scientific publications presenting comparisons of PDIP and AAA –
algorithms in portal dosimetry were not found.  
This thesis consists of two parts: a review of the literature and the practical part of the 
study. The review of the literature covers the principles of radiation therapy in brief and 
the dosimetric QA of treatment plans in more detail. The practical part of the study con-
sists of a dosimetric performance study comparing the measurement results applied by 
Varian portal dosimetry with aS1200-EPID to measurement results applied by I’mRT Ma-
triXX Evolution –array detector.  
48 clinical stereotactic treatment plans from three different target sites (20 brain, 19 lung 
and 9 prostate) previously treated in Tampere University Hospital (TAUH) were included 
in this retrospective study. The treatment plans comprise a comprehensive set of typical 
clinical cases. The treatment plans were planned according to the clinical protocols of 
stereotactic treatments, carried out with volumetric modulated arc therapy (VMAT) tech-
nique applying FFF-beams (6 MV FFF or 10 MV FFF). All the treatment plans were 
measured with both measurement systems and portal dosimetry measurements were 
performed with both portal prediction algorithms (PDIP and AAA) for treatment plans with 
6 MV FFF –beams. The gamma index analysis was performed after the measurements. 
This thesis is divided into seven chapters. Chapter 1. presents an introduction and the 
aim of this thesis. Chapter 2. introduces the theoretical background of the study, pre-
senting the basics of the radiation therapy and dose calculation. Chapter 3. presents the 
dosimetric QA of treatment plans in more detail. Chapter 4. presents the materials and 
methods of the study. The results are presented in chapter 5. Chapter 6. discusses the 
results and chapter 7. concludes this thesis. 
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2. RADIATION THERAPY AND DOSE 
CALCULATION 
Radiation therapy is a cancer treatment method. Radiation therapy utilizes ionizing radi-
ation to destroy tumor cells. External radiation therapy is given using linear accelerators, 
which produce photon and electron radiation. In this thesis, we concentrate on external 
photon beam treatments of small targets with high radiation doses.    
The ionizing radiation destroys cells. The higher the total radiation dose, the higher is 
the amount of destroyed cells, both tumor cells and healthy cells. The survival curves 
describe the relationship of the cell survival and the radiation dose. (8) 
The radiation therapy is fractioned into several smaller fractions to spare normal tissue 
by repair of sublethal damages and repopulation. Fractionation also increases the tumor 
cell death by reoxygenation and redistribution. Fractionation schemes were developed 
experimentally. For relatively small tumors, high precision treatments with few high dose 
fractions have been developed. (8) 
2.1 Linear accelerator 
A linear accelerator (linac) is a device that utilizes high frequency electromagnetic waves 
to accelerate charged particles such as electrons to high energies in a linear tube. Elec-
tron beam can be utilized itself to treat superficial tumors near the skin surface. More 
common case is that the electron beam is bombarded to a high density target and pho-
tons are produced as Bremsstrahlung radiation. Photons penetrate much deeper in the 
tissue than the electrons. (9) 
The gantry of the linear accelerator can rotate 360° in the horizontal axis. The collimator 
rotates in the vertical axis. The isocenter is the point where the collimator axis and the 
rotation axis intercept. In isocentric treatment technique, the beams from different direc-
tions meet in the same point. (9) 
A schematic diagram of linear accelerator head is presented in figure 1. After the target, 
the photons travel through the primary collimators. After the primary collimators, flatten-
ing filters located in the carousel, can be set in the photon beam to flatten it. (9) 
An ionization chamber is located after the carousel to detect symmetry and dose rate of 
the beams. After the ionization chamber, the beam is restricted by secondary collimators. 
The beam can be shaped statically or dynamically by multileaf collimator (MLC) which is 
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located the outmost in the treatment head. The leaves of the MLC move appropriately 
during the radiation treatment. (9) 
 
Figure 1. Schematic diagram of linear accelerator head. 1) Target 2) Primary colli-
mators 3) Flattening filter 4) Ionization chamber 5) Jaws 6) MLC 
2.1.1 Multileaf collimator 
Varian TrueBeam STx linac, used in this study, is equipped with high definition MLC 
(HDMLC) with 120 leaves. In Varian MLC, the ends of the leaves are rounded in order 
to ensure relatively constant penumbra at different positions in the field. The HDMLC 
leaves have a curvature of 16 cm. A schematic illustration of HD120™ MLC leaf tip shape 
is presented in figure 2. (10) 
 
Figure 2. Schematic illustration of leaf tip shape of Varian HD120 MLC  
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The leakage between adjacent leaves is minimized by the tongue and groove arrange-
ment. The motion of the leaves is rectilinear. The rectilinear motion and rounded leaf 
ends in combination introduce a nonlinear dependence of field size on leaf position. In 
dynamic MLC treatments, the delivered photon fluence is sensitive to the transmission 
through the leaves and the rounded leaf ends as well as the leakage between the leaves 
and the head scatter. (10) 
2.1.2 Flattening filter free photon beams 
In conventional linacs, the photon distribution produced in the target is peaked: the in-
tensity of the radiation field is higher in the central axis of the radiation field. Flattening 
filters are utilized to create flattened beams [6MV FFF (6 FFF), 10 MV FFF (10 FFF)], 
but a large proportion of the beam intensity is removed by the flattening filters reducing 
the highest possible dose rate. The majority of this intensity is converted into scattered 
radiation. The conventional radiation therapy techniques required flattened fields, but 
with intensity modulated techniques, a non-uniform beam profile can be taken into ac-
count in the treatment planning system during the inverse optimization. The advantages 
of the FFF beams are shorter treatment times due to the higher dose rates and reduction 
of the out-of-field dose due to the absence of scatter and leakage from the flattening 
filter. A schematic illustration of flattened and unflattened beam profiles are presented in 
figure 3.  (6, 11, 12) 
 
Figure 3. Schematic illustration of flattened (6X and 10X) and unflattened (6FFF 
and 10FFF) beam profiles. 
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2.2 Intensity modulated radiation therapy  
Intensity modulated radiation therapy (IMRT) is a treatment technique in which the inten-
sity of the beam in different parts of the radiation field is modified. IMRT enables precise 
conformation of the radiation dose to the target volume allowing more normal tissue to 
be spared than with other techniques. On the other perspective, the tumor dose can be 
increased with IMRT, compared to the conventional techniques, without increasing the 
dose in the surrounding critical tissues. However, small doses cover larger regions in the 
body compared to the traditional planning techniques. (9, 13) 
IMRT has two key features compared to the conventional radiotherapy: non-uniform in-
tensity of the radiation beams and inverse planning. The inverse planning is a planning 
method in which the desired dose distribution in the means of clinical objectives are set 
at first, and then the treatment parameters are determined by optimization to achieve the 
desired dose distribution. Optimization criteria have to be described in a quantitative 
form, normally as dose limitations for target and critical structures. The optimal dose 
distribution is calculated using an iterative mathematical method. As a result, the dose 
distribution fulfils given criteria in an optimal way, depending on the mathematical method 
and the optimization criteria. If optimization criteria are opposing each other, the optimi-
zation needs to make a compromise. The result is also affected by the starting point of 
the optimization, which is characterized usually by the selection of the radiation type and 
energy, the number of fields, treatment technique, field angles, collimator angles and 
field sizes. The starting point definition makes calculations faster by restricting the op-
tions. At the same time, it also restricts the degrees of freedom in optimization and the 
most optimal dose plan. The starting point definition might need revision, if the dose plan 
does not meet the given criteria. (9, 13) 
VMAT is an IMRT technique in which the dose is delivered dynamically during the rota-
tion of the gantry: 360 degrees of beam directions are available for optimization. VMAT 
utilizes also dynamic MLCs and dose rate. MLC leaf motion and number of monitor units 
(MU) per degree of gantry rotation are restricted during the optimization. (14) 
2.2.1 Modulation 
IMRT/VMAT technique enables conformal dose distributions in targets and sparing of 
normal tissues by concave shaped distributions. The most optimal dose distribution is a 
trade of complexity of the treatment plan and the desired dose distribution. As the com-
plexity increases, also the degree of modulation increases and the accuracy of the plan 
delivery might decrease. An optimal treatment plan has good enough dose distribution 
with as low degree of complexity as practically possible. As the modulation of the beam 
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increases, a large number of small and irregular beam apertures are used. The number 
of MUs increases as the MLC blocks the beam for increasing amount and the radiation 
energy is lost in the primary beam and the secondary radiation is increased due to the 
scatter and transmission through the MLC leaves. The increase of modulation degree 
increases also the dose calculation uncertainties, as well as MLC movement, gantry 
movement and dose rate uncertainties. As a result, the increase of modulation degree 
increases the probability of dose delivery errors and the intended dose distribution might 
not be delivered accurately to the patient. (15) 
2.3 Dose calculation  
A clinical beam is represented by a photon beam source model in Varian Eclipse treat-
ment planning system. The photon beam source model consists of four main sources: 
primary photon source, second photon source, electron contamination source and 
wedge scatter source. (16) 
The primary source of the photon beam source model is a point source located at the 
target plane. The primary source models the bremsstrahlung photons created in the tar-
get, but does not take into account the photons that interact with the treatment unit head. 
The second source is a Gaussian plane source. It is located at the bottom of the flattening 
filter. It models the photons that result from interactions in the treatment unit head. In 
case of FFF-beams, the second source is not taken into the calculations, as the flattening 
filter is removed from the beamline and since the most important source of scattering is 
not present. (16) 
Electron contamination describes the dose deposited in the build-up region that the pri-
mary and the second source models do not take into account. It also models the photon 
contamination due to the electron interactions. The electron contamination model is a 
depth-dependent curve and it describes the total amount of electron contamination dose 
at a certain depth. In the wedge scatter source, each point in the wedge acts as a scatter 
source. The intensity of the scattered radiation is proportional to the amount of primary 
radiation hitting that point. (16) 
The dose calculation algorithm used routinely in our clinic is the algorithm originally con-
ceived by Dr. Ulmer and Dr. Kaissl (17), the Anisotropic Analytical Algorithm (AAA), 
which is a 3D pencil beam convolution/superposition algorithm. It uses separate Monte 
Carlo derived modeling for each source component. The AAA accounts for tissue heter-
ogeneity anisotropically by using photon scatter kernels in multiple lateral directions. (16) 
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The patient scatter model is used for the dose deposited inside the patient and the phase-
space parameters describe the treatment beam upstream of the patient. The broad treat-
ment beam is divided into finite-sized beamlets. The beamlets are modelled using sev-
eral monoenergetic scatter kernels, which describe the phantom-scatter. The size of the 
beamlets is determined by the resolution of the calculation grid on the isocenter plane. 
The dose calculation is based on the convolutions over the beamlet cross-sections sep-
arately for each source model component. (16) 
The patient body volume is divided into a matrix of 3D voxels to calculate the volumetric 
dose distribution. The geometry of the calculation voxel grid is divergent due to the di-
vergent beam fanlines. Calculation voxels are associated with the mean electron density 
that is computed from the patient computed tomography (CT) images according to a 
user-specified calibration curve. The 3D dose distribution is calculated from separate 
convolutions for different sources in the source model. The convolutions are performed 
for the broad treatment beam which comprises all finite-sized beamlets. The final dose 
is obtained by a simple superposition of the individual beamlet contributions. (16) 
The photon beam attenuation is modelled with an energy deposition density function and 
the photon scatter is modelled with a scatter kernel that defines the lateral energy scat-
tering. The photon beam attenuation and the scatter kernel are defined individually for 
each beamlet. The calculations of the primary source and the other photon sources differ 
only by the spectral composition and the position and size of the focal spots. The dose 
convolution is performed in terms of energy, which allows more accurate energy conser-
vation even in complex heterogeneous convolutions. Finally the scaled-water approxi-
mation is used to convert the energy to dose. (16) 
2.3.1 VMAT calculation 
In Varian Eclipse treatment planning system, the optimization of IMRT/VMAT plans can 
be done by Photon Optimization Algorithm (PO) or Progressive Resolution Optimizer 
(PRO) algorithm. The PO algorithm combines the previous Varian optimization methods 
used for static field IMRT and arc field IMRT with Dose Volume Optimizer- and PRO-
algorithms. The main difference of the PO algorithm from the PRO algorithm is that the 
PRO-algorithm uses a point cloud model for defining structures. The PO algorithm uses 
a structure model for defining structures, where structures, dose volume histogram cal-
culation and dose sampling are defined spatially by using one single matrix over the 
image. (16) 
The optimization algorithms PO and PRO create VMAT plans, which use dynamic MLC 
(dMLC), variable dose rate and variable gantry speed, based on dose-volume objectives. 
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A sequence of control points is generated to define MLC leaf positions and MUs per 
degree as a function of gantry angle. MUs per degree are encoded with the cumulative 
meterset weight, defining the increase in monitor units between control points relative to 
the total MUs in the field. This information is transferred to the treatment machine and 
the machine control system determines how dose rate and gantry speed will be modu-
lated to deliver the plan. (16) 
An objective function, the sum of the dose-volume and other user-defined objectives, is 
used to optimize the plan and to evaluate its quality. The PO and PRO algorithms use a 
progressive resolution principle. The initial conditions are defined using control points to 
represent each VMAT field. At first, the dose is modelled using a lower number of dose 
calculation segments evenly distributed in each field. The number of segment increases 
from one multi-resolution level to the next. The dose in each segment is calculated from 
the combined fluence through the MLC aperture at the control points located within a 
certain sector of the arc. Leaf motion is modelled by interpolating leaf positions between 
the control points. Leaf tongues are taken into account by modifying the MLC aperture 
outline to effectively account for the tongue-and-groove effect. The number of control 
points remains the same during the whole optimization, but the angle resolution of the 
dose calculation segments gets more accurate as the optimization progresses leading 
to the more accurate dose calculation. The optimization algorithms give their results as 
fluences. (16) 
In Eclipse, the final dose calculation for all MLC fields is based on fluences. All fluence 
delivery modelling algorithms take into account the leaf transmission, dosimetric leaf gap 
and tongue-and-groove modelling. These features are also taken into account in the PO 
and PRO algorithms, as well as in the final fluence calculation for MLC fields. (16) 
A leaf motion calculator (LMC) program calculates the dMLC leaf motion pattern to de-
liver the dose defined by the optimal fluence. Taking into account the physical and me-
chanical characteristics of the MLC device, the resulting fluence is an actual fluence that 
approximates the optimal fluence. (16)   
Four parameters are required in the commissioning of the Varian MLC: leaf position off-
set (LPO), radiation field offset (RFO), dosimetric leaf gap (DLG) and the MLC transmis-
sion. 
There are three possible projections of the rounded leaf ends at the isocenter, the geo-
metric position, the physical position and the projected position. The geometric position 
is defined by the light field. The physical position is defined by the radiation field edge 
defined as the 50% isodose line. The projected position is defined by Varian in a MLC 
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file which links the projected position with the light field (LPO), as the projected position 
has a nonlinear dependency with the light position. RFO is defined as the difference 
between the geometric position and the physical position. The Varian Eclipse defines the 
nominal position of the MLC in the light field. The algorithm decreases the MLC position 
values by the constant RFO parameter in order to align the nominal MLC position with 
the modelled radiation field. (18)  
DLG 
DLG is a parameter which takes into account the partial transmission through rounded 
leaf ends of the MLC. The MLC is modelled as straight edged in the Eclipse treatment 
planning system, and the dose calculation in Eclipse retracts the MLC leaf positions by 
half of the DLG for all leaf positions in a dMLC plan to model the rounded leaf ends. As 
each leaf tip is retracted by half of the DLG, the gap between the fully closed leaf pair 
equals the DLG.  (16, 19) 
The DLG models the difference between the radiation and light field accounting for in-
herent leakage between leaf tips. The DLG in the treatment planning system is deter-
mined during commissioning of the linac and is set individually for each energy in the 
linear accelerator.  It can be measured by extrapolating the size of static or dynamic 
fields formed by MLC leaves to the size under which the measured dose equals the MLC 
leakage. Due to the uncertainties, the use of measured DLG in a dose calculation algo-
rithm often results with lower agreement than expected between the planned and the 
measured dose. The higher failure rates are reported with very large or very small target 
volumes surrounded by sensitive organs. Large number of monitor units are required in 
a single fraction high dose treatments and the accuracy of leakage calculations becomes 
a critical issue as it accounts for much of the patient dose. (18-21)  
The DLG can be measured with a series of dMLC setups (10). The dose of the sweeping 
gap dMLC motion with various gap widths is measured. The measured leaf transmission 
is subtracted from the sweeping gap measurements. The corrected sweeping gap meas-
urements are plotted against nominal gap width and regression is fitted to the measure-
ment points. DLG can be obtained by extrapolating the regression line to zero measure-
ment and reading the corresponding gap width. The extrapolated gap width should be 
negative and DLG is the absolute value of it. (16) 
MLC transmission 
The MLC leaves do not block the radiation completely. Small amount of radiation trans-
mits directly through the leaves. The transmission factor is a ratio of the measured dose 
in an open field of certain field size and the measured dose with the same field size, but 
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all the MLC leaves closed behind the jaws. The leaf transmission factor describes the 
average transmission through the MLC leaves, but does not take into account the local 
variations in leaf width or in the energy spectrum of the beam. (16)   
In the leaf travel direction, the path length of the beam through the MLC leaves increases 
as the off-axis distance increases. This decreases the intraleaf transmission at off-axis 
distances along the MLC travel direction. In the direction perpendicular to MLC motion, 
the leaves are arranged to follow the divergence of the beam and thus the path lengths 
are equal. Despite the equal path lengths, the intraleaf transmission through the central 
40 MLC leaf pairs (width 0.5cm) is greater than the outer leaf pairs (width 1.0cm). (19) 
Tongue-and-groove 
To minimize the inter-leaf leakage, the Varian MLC device models have a tongue-and-
groove design. The tongue of the MLC blocks some of the additional radiation and the 
amount is proportional to the ratio between the tongue and the leaf widths. This is called 
the tongue-and-groove effect. This effect is modelled in the fluence delivery algorithms 
by extending the leaf projections in the direction perpendicular to the leaf motion with an 
approximate extension parameter, which is slightly smaller than the real tongue width. 
(16)    
2.4 Stereotactic radiation therapy 
Originally high precision radiation therapy treatments were given using external coordi-
nates and the treatment was called stereotactic radiation therapy. Originally stereotactic 
radiosurgery (SRS) treatments were given solely on small targets in the brain. Stereo-
tactic frame was screwed on a surface of the scull bone (before treatment planning com-
puted tomography imaging) for a single fraction treatments. For treatments with several 
fractions, the stereotactic frame was attached on a mask system made of thermoplastic 
material. (13) 
Later on stereotactic body radiation therapy (SBRT) with a stereotactic body frame and 
finally frameless stereotactic treatments were developed. In frameless stereotactic treat-
ments, the external coordinates are set based on the markers on the patient skin, instead 
of the external frame. Nowadays all the high precision treatments are based on the 
frameless stereotaxy and no frames are used any more. However, the term “stereotactic 
treatment” is still in use, although the high precision treatments are not based on external 
coordinates any more. To assure accurate tumor localization, proper patient immobiliza-
tion, motion limitation and modern image guidance are needed.(13) 
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Stereotactic treatments are characterized by the small target volumes treated by a single 
high dose or few fractionated doses. Fractionated stereotactic treatments are usually 
given in a few (2-3) fractions a week, instead of the 5 fractions a week (conventional 
treatments). The number of fractions is low (1-5 fractions) compared to the conventional 
treatments (20-30 fractions). The aim of the stereotactic treatments is to get a steep dose 
gradient between the target and the organs next to the target, in order to minimize the 
volume of the healthy tissue that is affected by the high radiation dose. (2)  
SRS for brain has showed the clinical usefullness in the treatment of brain tumors. SBRT 
is highly effective in early stage primary and oligometastatic cancers in abdominopelvic 
and thoracic areas, as well as at spinal and paraspinal locations. The stereotactic treat-
ments result in a high biological effective dose (BED) and require high level of accuracy 
in the entire treatment delivery process. In general, larger number of beams are needed, 
as well as non-coplanar beam arrangements, compared to the conventional treatments. 
(22) 
Nowadays, the use of VMAT treatment technique in stereotactic high-precision treat-
ments is increasing. ESTRO ACROP Guideline of SBRT for peripherally located early 
stage non-small cell lung cancer recommends VMAT for best practice (23). In VMAT 
treatments, multiple arcs are required to deliver large fraction doses and FFF-beams are 
utilized to minimize the treatment time. 
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3. DOSIMETRIC QUALITY ASSURANCE OF 
TREATMENT PLANS 
3.1 Small field dosimetry 
Advanced radiation therapy techniques with increased tumor dose and decreased dose 
at organs at risk in means of steep dose gradients have increased the accuracy require-
ments for dose delivery to patients. The QA of treatment plans is one important step to 
guarantee the accuracy requirements. (24) 
For conventional radiation therapy, dosimetry protocols are based on well-established 
practices based on measurements using an ionization chamber. The ionization chamber 
measurements require calibration coefficient in terms of absorbed dose to water, which 
is traceable to a primary standards dosimetry laboratory for reference conditions. Now-
adays, the advances in radiotherapy treatments has led to the use of small fields of a 
subcentimeter scale in radiation therapy, compared to the traditional radiation therapy 
fields from 4 x 4 cm2 to the 40 x 40cm2. The dramatic increase in the amount of small 
fields utilized in radiotherapy treatments is due to the use of MLC collimated beamlet-
based IMRT and VMAT treatment techniques, especially in stereotactic treatments. The 
dosimetric accuracy previously achieved for standard treatments is at risk for both abso-
lute and relative dosimetry due to the characteristics of small fields presented in the next 
paragraphs. (25, 26) 
The small field can be defined by the following conditions: 
1) Loss of a charged particle equilibrium on the beam axis 
2) Partial occlusion of the primary photon source by the collimating devices on the 
beam axis. 
3) The size of the detector is similar or large compared to the beam dimensions. 
These conditions result in overlap between the field penumbrae and the detector volume. 
The field is considered as a small field, if at least one of these conditions apply. (25) 
To measure the absorbed dose in a medium, a dosimeter have to be embedded into the 
medium. However, in most cases the sensitive medium of the dosimeter is not the same 
material as the measured medium. Cavity theory relates the absorbed dose in the do-
simeter cavity to the absorbed dose in the measured medium. Bragg-Gary cavity theory 
provides a relationship between the absorbed dose in a dosimeter and the absorbed 
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dose in the medium containing the dosimeter. The Bragg-Gray cavity theory conditions 
are that the “cavity is small compared to the range of charged particle incident on it” and 
“the absorbed dose in the cavity is deposited solely by charged particles crossing it”. 
Under these conditions, the dose in the medium is related to the dose in the cavity by 
the ratio of the average unrestricted mass collision stopping powers of the medium and 
the cavity, according to the Bragg-Gray cavity theory. (27) 
Secondary electrons with finite range are released through photon interactions in mate-
rial. Secondary electrons contribute measurably to the absorbed dose. If the number of 
charged particles entering and leaving the volume is equal, the charge particle equilib-
rium occurs. The loss of lateral charged particle equilibrium occurs if the beam half width 
is smaller than the maximum range of the secondary electrons. As a result, the delivered 
dose to the active volume of the detector is unequal to the dose created by the same 
electrons from the opposite edge in the lateral direction. In case of small fields, the lateral 
range of electrons is usually larger than the field size. (25, 28) 
The primary source of the treatment unit has a finite size. It is determined by the full width 
half maximum of the bremsstrahlung photon fluence distribution exiting the target. In 
case of the small field, the field collimation can shield the part of the finite primary photon 
source, producing a lower beam output compared to the unshielded situation of larger 
fields. The partial occlusion of the primary source has an influence on the particle spec-
trum as well as is a source of steep gradients in local absorbed dose. The both phenom-
ena can have a significant effect on the detector response as well as cause a sharp drop 
in beam output as the field size decreases. The larger the energy or the smaller the 
density of the medium, the more pronounced the phenomenon. In case of the partially 
shielded primary source, the geometrical penumbra is extended all over the field cross 
section. This leads to the problem that the traditional field size determination based on 
full width at half maximum breaks down and underestimates the field size. In addition to 
these challenges, the characteristics of the MLC cause more challenges for the field size 
determination. (25, 26, 28) 
The radiation detector in the radiation field produces a signal proportional to the mean 
absorbed dose over the sensitive volume of the detector. In case of the small radiation 
field size relative to the detector size, the inhomogeneity of the absorbed dose over the 
detector volume affects the signal received, as only a part of the detector volume is ex-
posed to irradiation. This phenomenon is called volume averaging. As a result, the meas-
ured beam profiles are flattened: the dose in the field center is measured to be lower 
than actual, and the dose beyond the field edge is overestimated.  In addition to the 
volume averaging, the presence of the detector causes the perturbation of the charged 
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particle fluence leading to the deviation from the Bragg-Gray cavity theory conditions. 
When the dose gradient is steep and there is a loss of the lateral charged particle equi-
librium, these difficultly modelled fluence perturbations become large. (25, 26, 28) 
In addition to the shielding of the primary photon source, the small field collimation de-
creases the amount of scattered radiation from the treatment head by shielding also the 
head scattered photons. As a result, low energy photons are absorbed by the collimators. 
In case of small fields, the amount of phantom scatter decreases compared to the con-
ventional field sizes. This phenomenon of reduced phantom scatter is even more pro-
nounced than the reduction of the head scatter. In combination, these two phenomena 
result in photon beam hardening increasing the average photon energy compared to the 
conventional fields. On the other hand, this beam hardening results in a change of the 
ratio of mass energy absorption coefficients as well as stopping-power ratio between 
water and the detector material. (25) 
3.1.1 Relative dosimetry 
The dosimetry of radiation therapy can be divided into two main categories, to relative 
dosimetry and absolute dosimetry. The absolute dosimetry covers only the dose calibra-
tion of treatment unit in water phantom with ionization chamber calibrated in standard 
dosimetry laboratory. All the other quality assurance measurements are relative to the 
absolute dose measurements. The relative dosimetry is independent of many correction 
factors required in absolute dosimetry, such as pressure-temperature correction and re-
combination correction, as the correction factors are not relative to the location of the 
detector in the radiation field. Instead, the measurement in one arbitrary point can be 
divided by the measurement in reference point and as a result, the relationship of ab-
sorbed doses in those points are defined. (13)   
Nowadays each patient treatment plan is customized and unique. In IMRT/VMAT treat-
ments each treatment field can be highly complex and QA is required to verify the treat-
ment planning system’s ability to calculate the dose accurately and to verify the ability of 
the treatment unit to deliver the planned dose accurately. In addition, the mechanical 
inaccuracies can lead in significant measurement errors. (13), (29) 
The commissioning and QA of 3D-treatment planning system requires comparison of 
measured and calculated dose distributions. Dose distribution can be measured in a 
plane perpendicular to its axis or in a phantom. In this thesis we concentrate on meas-
urements in a plane perpendicular to its axis. The measured dose distributions are com-
pared with the predicted distributions from the treatment planning system. (12) 
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3.2 Gamma index analysis 
Gamma index evaluation is a standard technique to quantitatively evaluate measured 
distributions against the dose distributions predicted by the treatment planning systems. 
The gamma analysis is needed for film, array dosimeter and portal dosimetry measure-
ments as those measurement methods consists of multiple measurement points. The 
gamma index analysis combines the dose difference and the distance to agreement cri-
teria to calculate a dimensionless metric for each point in the evaluated distribution. (30) 
In low gradient regions, the doses can be compared directly. The acceptance tolerance 
is set for the difference between measured and calculated doses. On the other hand, in 
high dose gradient regions, a small spatial error can result in a large dose difference. In 
this case the dose difference is not a good measure of acceptability and distance-to-
agreement (DTA) distribution is used to determine the acceptability of the dose calcula-
tions in high dose gradient regions. DTA is defined as a distance between a measured 
data point and the nearest calculated point in which the dose value is equal to that meas-
ured value. As a result, the dose difference and the DTA evaluations complement each 
other in the dose distribution analyses. (4)  
An interpolation of the evaluated dose distribution is required for gamma analysis, when 
the measurements are widely spaced relative to the DTA criterion. A gamma value of <1 
indicates that a point lies within the dose difference / distance to agreement passing 
criteria. Common passing criteria are, for example, 3%/3 mm and 2%/2 mm. In a quality 
assurance routine, the total percentage of points having gamma index <1 is calculated 
and a pass/fail threshold is set. A common passing threshold is 95%. (30) 
The gamma value for the measured point rm is defined by the following formulae: 
𝛾(𝑟𝑚) = min {√
|𝑟𝑐 − 𝑟𝑚|2
∆𝑑𝑀
2 +
[𝐷𝑐(𝑟𝑐) − 𝐷𝑚(𝑟𝑚)]2
∆𝐷𝑀
2 } ∀{𝑟𝑐} 
𝑟𝑚  position of a single measurement point 
𝑟𝑐  spatial location of the calculated distribution relative to the measurement point 
∆𝑑𝑀  passing criteria for isodose distance 
∆𝐷𝑀 passing criteria for dose 
𝐷𝑐(𝑟𝑐)  calculated dose in 𝑟𝑐 
𝐷𝑚(𝑟𝑚) measured dose in 𝑟𝑚 
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The pass-fail criteria are: 
𝛾(𝑟𝑚) ≤ 1 calculation passes 
𝛾(𝑟𝑚) > 1 calculation fails 
This gamma calculation is performed for all rm. 
3.3 Point detectors 
Point detectors allow absolute dose validation at individual points, but they are not suit-
able alone to the validation and QA of IMRT/VMAT dose distributions. However, array 
detectors based on single point detectors are suitable for IMRT/VMAT quality assurance.  
3.3.1 Ionization chambers 
An ionization chamber is a gas filled cavity surrounded by a conductive wall. The collect-
ing electrode is placed in the center of the cavity and is separated from the wall with an 
insulator. The insulator and a guard electrode reduce the chamber leakage. Open air 
ionization chambers require temperature and pressure correction. An electrometer is re-
quired to measure small currents induced in the ionization chamber by ionizing radiation. 
Cylindrical ionization chambers are the most common measurement device for point-
dose measurements of photon radiation used in radiation therapy. The cylindrical ioni-
zation chambers exhibit excellent stability, small directional dependency, excellent linear 
response to absorbed dose, response independency of beam-quality and it is traceable 
to a primary calibration standard. The cylindrical symmetry minimizes the directional de-
pendency when the beam central axis is perpendicular to the chamber axis of symmetry. 
Ionization chambers used for beam calibration are waterproof and designed with air-
ventilation. (3) 
Volume averaging is a character that the ionization chambers exhibit always to some 
extent. As a result, the effect is the most pronounced in the beam penumbra regions. For 
possible IMRT measurements, to minimize the volume averaging effect, the ionization 
chamber is recommended to be placed in the region of relatively homogenous fluence 
and in the regions of relatively homogenous dose in case of total dose measurements. 
The volume averaging effect is more pronounced in small treatment fields, as the size of 
the detector is large compared to the size of the field. (3) 
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Stem effect is an effect in which the irradiated portion of the ionization chamber stem can 
induce leakage current perturbing the collected charge. This phenomenon is more pro-
nounced in small ionization chamber detectors, as the signal of these detectors is much 
weaker than signal of larger ionization chambers. (3) 
3.4 Array detectors  
Array detector is a dosimetric measurement device that comprises of a set of detectors, 
most commonly diode detectors or ionization chambers, placed in an array. The spacing 
between adjacent detectors define the spatial resolution of the device. In some array 
detectors, the spacing between detectors might be denser in the middle of the array and 
sparser in the outer parts of the array. To increase the spatial resolution, it might be 
possible to follow a measurement protocol in which the same treatment field is measured 
twice with a short offset in the array location to double the measurement points in the 
measurement area. Array detectors are calibrated to yield multiple cumulative reading of 
absorbed dose across a 2D plane to provide a large number of dose measurements in 
a single irradiation. The measurement results are available immediately. (3) 
The array detectors are developed especially for the QA of treatment plans. 2D arrays 
can also be used to check the beam symmetry. The QA of treatment plans with array 
detectors is based on the comparison of measured and predicted/calculated dose. The 
most common analysis method for array measurements is the gamma analysis. In addi-
tion to the gamma analysis, the dose difference solely is of interest when comparing 
measured and predicted dose. In order to compare measured and calculated dose 
planes, the array detector needs to be calibrated with a known field size and dose to be 
able to measure absolute dose level of the measurement field. In 3D array detectors, the 
detectors are formed in a 3D planes. (3) 
The 2D array detectors can be used as mounted in the gantry holder for IMRT measure-
ments and for VMAT measurement, they can be either mounted on the gantry holder or 
placed on the treatment table with a certain buildup material/phantom. In case of the 
gantry holder, the beam is coming perpendicularly to the array surface independent of 
the gantry angle and the actual summation of 3D dose will stay unclear. In case that the 
array is located on the treatment table, the direction of irradiation reaching the detectors 
varies with the gantry angle. In such case, the angular dependency of the detectors 
needs to be taken into account. This method takes better into account the actual 3D 
summation of the dose. (3) 
19 
 
3.4.1 I’mRT MatriXX Evolution 
I’mRT MatriXX Evolution 2D array device (IBA Dosimetry GmbH, Schrwarzenbruck, Ger-
many), presented in the figure 4., consists of 1020 vented parallel ion chambers arranged 
in a 32 x 32 grid. The air in the ionizing chambers is ionized, when irradiated. The re-
leased charge is separated by the electrical field between the top and bottom electrodes. 
The electrical current is measured and digitized by a non-multiplexed 1020 channels 
current sensitive analog to digital converter. The active measurement area is 24.4 cm x 
24.4 cm, and the chamber diameter is 4.5 mm and height 5.0 mm resulting in a chamber 
volume of 0.08 cm3. The distance between adjacent chambers is 7.62mm measured 
from center to center. The OmniPro IMRT software enables 1 mm resolution with linear 
interpolation using low pass filter. The absorber thickness on top of the measurement 
device is 3 mm ABS Tecaran with density of 1.06 g/cm3, resulting in water equivalent 
depth of 3.1 mm. The effective point of measurement is 3.5 mm below the surface and 
is indicated by engraved markers on the housing sides. (31) 
 
Figure 4.  I’mRT MatriXX Evolution array detector 
Saminathan et al. (32) evaluated the dosimetric characteristics of I’mRT MatriXX. The 
basic dosimetric evaluation included output factor, dose linearity and dose rate depend-
ency. In addition, IMRT treatment plan measurements with I’mRT MatriXX were com-
pared with film measurements. The response of the I’mRT Matrixx in dose measure-
ments was linear for all the energies measured from 2 to 500 MU. The dose rate meas-
urement proved the I’mRT MatriXX to be independent of dose rate between 100 MU/min 
to 600 MU/min for all the energies measured. The observed results were in close agree-
ment with ion chamber measurements. These measurement proved that the device can 
be used for the measurements of dose gradients. The output measurements with I’mRT 
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MatriXX were in close agreement with the ionization chamber measurements (6 MV and 
18 MV) and the parallel plate ionization chamber measurements. Discrepancies of ± 
0.5% were found, resulting possibly from the scatter arising from the components of the 
array. Gamma analysis (3%/3 mm) revealed good agreement for test patterns and clini-
cal treatment plans in I’mRT MatriXX and film measurements. They conclude that ac-
cording to their measurements, the I’mRT MatriXX array detector can be used for quan-
tifying absolute dose with the required accuracy level. (32)  
3.5 Portal dosimetry 
Varian linacs are equipped with EPIDs, which were originally designed for patient posi-
tioning as a MV imagers. kV- on board imagers have replaced the MV imagers as a 
patient positioning device due to their better soft tissue contrast. Due to EPIDs’ high 
sensitivity, special resolution and immediate digital format, EPIDs have been utilized for 
patient plan quality assurance. (21) 
The first commercial EPIDs were based on liquid-filled ionization chambers or cameras. 
Nowadays, the most commonly available EPIDs are active matrix flat panel imagers 
based on amorphous-silicon (aSi). The imager panel consists of an X-ray converter, a 
light detector, and a processing unit, hence the aSi EPID systems are based on indirect 
method. (24) 
 
Figure 5. Varian aS1200 EPID on Truebeam STx linac 
The scintillator converts the incident radiation into visible photons. The visible photons 
are sensed by an array of photodiodes in the amorphous silicon panel and they integrate 
the incoming light in an electric charge. The electrical charge is accumulated in the pho-
todiode until the signal is read out and digitized. In Varian aS1200 EPID, presented in 
figure 5, the charge information is transferred to the readout electronics by activating the 
pixel matrix row by row while the columns are read out. The charge is converted into 
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digital form which results in a discrete value in each pixel. The TrueBeam system pro-
vides three MV image acquisition techniques triggered by the Supervisor: Single MV 
radshot for setup images, Synchronized MV for cine and single image acquisition and 
Unsynchronized MV for dosimetry. In dosimetry mode, dose/frame is kept constant by 
adapting frame rate. Varian aS1200 EPID is a matrix detector with resolution of 0.03 cm2. 
The total sensitive area is 40 x 40 cm2 with 1190x1190 pixel arrays, pixel pitch 0.336 
mm. The aS1200 EPID is attached to the gantry through a robotic arm. A backscatter 
shielding is included in the cassette design to avoid the scattered radiation from the ro-
botic arm. (21, 33) 
EPIDs are quick and easy to use compared to the detector array measurements. They 
also enable finer spatial resolution compared to the array detectors. EPID enables meas-
urements of single treatment fields in a perpendicular manner, as the EPID is mounted 
in the gantry opposite to the treatment head. A number of corrections needs to be applied 
to convert the signal detected by the EPID into the fluence or dose in the detector plane. 
The predicted calculated dose is typically determined at the plane of the detector as a 
portal dose image by the treatment planning system. (3) 
Varian offers two algorithms with portal dose calculation capability for the aS1200 detec-
tor: Portal Dose Image Prediction (PDIP) and AAA. The portal dose measurements can 
be performed at any source to detector distance (SDD), but the optimum accuracy can 
be achieved by using a single SDD as close to the isocenter as possible for all the meas-
urement steps (the calibration, configuration and portal acquisition).(34) 
PDIP algorithm is a standalone algorithm which is configured independently of any other 
algorithms. It calculates the planned fluence by summing up the individual aperture flu-
ences from control points of the field taking also into account the dynamic dose rate as 
well as the accumulated fluence between control points. The predicted portal dose image 
is determined at the EPID’s detector plate ignoring the couch or the patient and the image 
is produced in terms of calibrated unit (CU). (5)  
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According to Varian Eclipse Photon and Electron Algorithms Reference Guide (34), PDIP 
calculates the portal dose image by convolving the fluence with Gaussian kernels as: 
 
𝑃 = 𝑓′ × 𝑘 ∙ (
𝑆𝐴𝐷
𝑆𝐷𝐷
)
2
(
𝑂𝐹(𝑓𝑠𝑥, 𝑓𝑠𝑦)
𝑃𝑆𝐹(𝑓𝑠𝑥, 𝑓𝑠𝑦)
) 
where 
𝑃 =     Calculated portal dose image in terms of CU 
𝑓′ =    Input fluence corrected by the intensity profile and scaled by detec-
tor distance 
× =    Convolution operator 
𝑘 =    Portal imager dose kernel 
𝑆𝐷𝐷 =   Source-to-detector distance of the portal image measurement 
𝑆𝐴𝐷 =   Source-to-axis distance of the treatment unit 
𝑓𝑠𝑥 =    Field size at the SAD in the FX-direction 
𝑓𝑠𝑦 =    Field size at the SAD in the FY-direction 
𝑃𝑆𝐹(𝑓𝑠𝑥, 𝑓𝑠𝑦) =  Phantom scatter factor for field size 𝑓𝑠𝑥, 𝑓𝑠𝑦, defiend at SAD 
𝑂𝐹(𝑓𝑠𝑥, 𝑓𝑠𝑦) =  Output factor for field size 𝑓𝑠𝑥, 𝑓𝑠𝑦, defiend at SAD and normalized 
to a 10x10 cm2 field in terms of CU  
(34) 
The AAA can be used for portal dose calculation with the same configured beam data 
as used for patient dose calculation. However, currently AAA can be used only for portal 
dose calculation of 6 FFF beams and for the aS1200 detector. A portal image is calcu-
lated in terms of CU at the detector aS1200 plate, ignoring the treatment couch and the 
patient. The AAA performs the dose calculation with an internal model of the aS1200 
detector. In order to predict the appropriate dose response of the detector, the algorithm 
uses scatter kernels calculated in the imager scintillator material. (34) 
For portal dosimetry, the EPID is working on the dosimetric mode acquiring image frames 
during irradiation. The irradiation happens undisturbed, as there is no synchronization 
between linac and EPID. Previously, the problem has been that the high dose rate of 
FFF-beams led to a saturation of EPID and to the loss of information, as the amount of 
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radiation was too high between two frames. In aS1200 EPID, this problem has been 
solved. (12) 
The calibration of EPID is required regularly. The calibration procedure includes the fol-
lowing steps: dark field, flood field, pixel defect map and absolute dose calibration. The 
SDD for calibration process with Varian TrueBeam system is 100 cm.  The dark field is 
an acquisition without radiation. The flood field is an acquisition of a field covering the 
whole detector plate. The pixel defect map is computed based on the dark and the flood 
fields, and is corrected by averaging the neighboring pixels. The absolute dose calibra-
tion is performed by irradiating a 10 x 10 cm2 field with a known number of MUs, assigned 
to Calibration Units (CU), for all the energies needed for portal dosimetry.(12)   
Miri et al. (21) performed a basic dosimetry commissioning on the aS1200 EPID and 
TrueBeam 2.0 linac for flattened (FF) and FFF bams. Dosimetry testing included tests 
for linearity of dose response with MU, imager lag and effectiveness of backscatter 
shielding. The dose linearity of the EPID was within 0.4% above 5 MU and 1% above 2 
MU. The imager lag was extremely small compared with previous EPID versions and no 
increase in image signal with MU was found. The symmetry of the beam profiles for EPID 
was considerably improved from the previous EPID models, proving the backscatter 
shielding to be effective in the aS1200 EPID model. These results suggest that the 
aS1200 has excellent dosimetric properties compared to the previous EPID models. (21) 
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4. MATERIALS AND METHODS 
All the verification plans were delivered on a Varian TrueBeam™ STx accelerator 
equipped with a high-definition multileaf collimator HD120™ intended for stereotactic 
treatments and aS1200 electronic portal imaging device. The 32 central leaf pairs span-
ning 8 cm are 2.5 mm wide (projected at isocenter) and the outer leaf pairs spanning 
outer 14 cm 5 mm wide (projected at isocenter), the total number of leaves being 120. 
The radius of curvature of rounded leaf ends is 16 cm.  
4.1 Treatment plan selection 
For this retrospective study, 48 treatment plans were selected from three different target 
sites (20 brain, 19 lung and 9 prostate tumors), previously treated in TAUH. Single target 
plans were chosen to be evaluated to avoid convolving issues due to multiple targets. All 
the treatment plans were planned according to the clinical protocol of stereotactic treat-
ments, carried out with VMAT technique applying FFF beams. Treatment plans included 
in this study comprise comprehensive set of typical clinical cases from each target site 
group with most typical fractionation schemes. All the treatment plans were generated 
using Eclipse treatment planning system version 13.6. Dose calculation algorithm was 
AAA (version 13.6.23) and calculation grid was isotropic 1.0 mm for brain and lung tu-
mors, and 2.5 mm for prostate tumors. Box plot-distributions for planning target volumes 
(PTV) of different target sites are presented in figure 6A. Figure 6B. presents distributions 
of PTV volumes treated with 6 FFF and 10 FFF energies. Figure 6C. presents the distri-
butions of MU/Gy. Treatment plan properties including number of patients, fractionation 
schemes, energy, volume of PTV, number of VMAT arcs and MU/Gy are presented in 
table 1.  
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Figure 6. Box plot distributions of (A) PTV volumes, (B) PTV volumes treated with 6 
FFF and 10 FFF energies and (C) MU / Gy in categories of brain, lung and 
prostate tumors.  
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 Treatment plan properties 
Treatment 
site 
No. of 
patients  
Fractionation Energy Volume of PTV (cm3) 
No. of 
VMAT 
arcs 
MU/Gy 
Brain 20 
4 1x20Gy 
6MV 
FFF 
  Mean 6.39 
2-3 
Mean 260.6      
SD 37.2    
Min 179.4   
Max 343.7 
Mean 266.8 
 SD 4.5 SD 50.2 
3 3x 9Gy Mean 5.39   Min 0.83 3-4 Min 179.4 
3 5x 6Gy SD 4.27 Max 14.63 2 Max 343.7 
3 1x20Gy 
10MV 
FFF 
Min 0.83  Mean 4.40 
2 
Mean 254.3 
Max 14.63 SD 4.0 SD 17.75 
4 3x 9Gy  Min 0.88 2-3 Min 237.7 
3 5x 6Gy   Max 11.79 2 Max 295.0 
Lung 19 
2 3x18Gy 
6MV 
FFF 
  
Mean 
22.74  2 
Mean 319.7      
SD 70.9    
Min 227.2    
Max 503.7 
Mean 340.8  
 SD 19.3  SD 86.35  
6 5x11Gy Mean 25.32  Min 3.37 2 Min 243.3 
2 8x7.5Gy SD 18.6    Max 63.17  2 Max 503.7 
1 3x18Gy 
10MV 
FFF 
 Min 3.37     Mean 28.2  
2 
Mean 296.2 
Max 63.17 SD 18.4 SD 41.84 
6 5x11Gy  Min 6.21 2 Min 227.24 
2 8x7.5Gy   Max 60.97  2 Max 353.75 
Prostate 9 5x 7.25/7Gy 
10MV 
FFF 
Mean 84.8 
2 
Mean 303.8 
SD 18.1 SD 18.9 
Min 57.5 Min 280.6 
Max 117.3  Max 334.0 
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4.1.1 Brain tumors 
Fractionation schemes in treatment plans measured in this thesis for brain tumors were 
1x 20 Gy, 3x 9 Gy and 5x 6 Gy. Target volumes ranged from 0.83 cm3 to 14.63 cm3. 6 
FFF (dose rate 1400 MU/min) and 10 FFF (dose rate 2400 MU/min) beam energies were 
used. The number of VMAT arcs was 2-4 per treatment. Depending on the tumor loca-
tion, either full arcs or partial arcs were used. VMAT optimization algorithm was PRO 
(version 11.0.31). An example of a typical treatment plan setting for a brain tumor is 
presented in the Appendix A. 
4.1.2 Lung tumors 
Fractionation schemes in treatment plans measured in this thesis for lung tumors were 
3x 18 Gy, 5x 11 Gy and 8x 7.5 Gy. Target volumes ranged from 3.37 cm3 to 63.17 cm3.  
6 FFF (dose rate 1400 MU/min) and 10 FFF (dose rate 2400 MU/min) beam energie 
were used. The number of VMAT arcs was 2-3 per treatment. Depending on the tumor 
location, either full arcs or partial arcs were used. VMAT optimization algorithm was PRO 
(version 11.0.31). An example of a typical treatment plan setting for a lung tumor is pre-
sented in the Appendix B. 
4.1.3 Prostate tumors 
Fractionation scheme in treatment plans measured in this thesis for prostate cancer was 
extreme hypofractionation scheme 5x 7.25/7 Gy. The region of prostatic urethra received 
7 Gy while the rest of the prostate PTV received 7,25 Gy using simultaneous-integrated 
boost technique. Clinical target volume (CTV) was the prostate and PTV was formed 
from the CTV adding 3mm margin posteriorly and 5mm elsewhere. The treatment tech-
nique was VMAT. Target volumes ranged from 57.49 cm3 to 117.27 cm3. 10 MV FFF 
(dose rate 240 0MU/min) beams was used. The number of VMAT arcs was 2 per treat-
ment. Two full were used. VMAT optimization algorithm was PO (version 13.6.23). An 
example of a typical treatment plan setting for a prostate tumor is presented in the Ap-
pendix B. 
4.2 Analysis criteria 
4.2.1 Gamma analysis 
The gamma analysis was performed for both portal and array measurements. The 
gamma passing rates for the following gamma criteria (dose difference / distance to 
agreement) were calculated: 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm.  
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Two threshold values were used: 5% and 60%. The threshold value determines the dose 
level included in the gamma evaluation: the pixels receiving dose less than the threshold 
value of the maximum dose were not included in the gamma evaluation. The threshold 
of 5% from the maximum dose removes the noise from the analysis, but the dose due to 
leakage radiation between MLC leaves is taken into account. The threshold of 60% from 
the maximum dose removes also the dose due to the leakage radiation. The passing 
rates for gamma values <1 were calculated indicating the points lying within the given 
dose value difference and distance to agreement criteria. 
4.2.2 Average percentual dose difference analysis 
The average percentual dose differences with the same threshold values as in the 
gamma evaluation (5% and 60%) were analyzed from the portal dose images by the 
following formula: 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑢𝑎𝑙 𝑑𝑜𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑜𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝐶𝑈)
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝐶𝑈 𝑖𝑛 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑖𝑚𝑎𝑔𝑒
 . 
Negative average percentual dose difference values indicate that the measured dose is 
smaller than the predicted dose.   
OmniPro-analysis software does not have a threshold tool for dose difference measure-
ments, so the average percentual dose differences could not be measured for the array 
measurements.  
4.3 Quality assurance of treatment plans with portal dosimetry 
The verification plan creation was performed in the Eclipse treatment planning system. 
Source-Imager distance (SID) for calculated image was 100 cm. The verification plans 
were created using the actual planned gantry angles (GA) and collimator angles (CA). 
The predicted images were calculated using the PDIP-algorithm (version 13.6.23). 
The portal dosimetry system was calibrated according to manufacturer instructions be-
fore the measurements. SID was 100 cm both in calibration and measurements. For 
measurements, the treatment couch top was removed and the GAs and CAs were the 
same as in the treatment plans to simulate the gravitational effects. The couch rotations 
were not included, as the portal imager has a fixed geometry with the gantry. The meas-
urement set up is presented in the figure 7. All the plans were delivered with the planned 
dose rate of 1400 MU/min (6 FFF) or 2400 MU/min (10 FFF).  
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Figure 7. Portal dose measurement set up  
The analysis of measured and predicted dose distributions was performed in the Portal 
Dosimetry –workspace. Measured and predicted images were aligned automatically be-
fore the analysis. The dose region for gamma analysis can be defined in Portal Dosimetry 
-workspace by two parameters: Region of interest (ROI) and threshold. In this study, only 
a threshold was used. All the verification plan fields were analyzed. 
4.4 Reference calculation for portal dosimetry with AAA 
In Eclipse version 15.5, AAA-algorithm (version 15.6.03) is configured also for portal 
dose calculation for 6 FFF beams in combination with the aS1200 electronic portal im-
aging device. All the treatment plans with 6 FFF energy (10 brain and 10 lung treatment 
plans) were recalculated for portal dosimetry with AAA-algorithm, re-measured and an-
alyzed with the same protocol presented in the chapter 4.3 to compare the validity of 
AAA algorithm in comparison with the PDIP algorithm. 
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4.5 Quality assurance of treatment plans with I’mRT MatriXX 
Evolution array detector 
The I’mRT MatriXX Evolution measurement work flow consists of a creation of reference 
dose distributions in the I’mRT MatriXX Evolution geometry, calibration of the array, 
measurements, and analysis of measured and predicted dose distributions with dedi-
cated software (OmniPro I’mRT System Version 1.7b).  
The reference dose distributions were calculated in the Eclipse treatment planning sys-
tem with AAA (version 13.6.23). The GAs and CAs were the same as in the treatment 
plans. Each field was placed into a separate verification plan. The isocenter was placed 
in the surface of the I’mRT MatriXX Evolution detector and in the middle of the detector 
area, as is the case in the measurements. The reference dose distributions were ex-
ported to the OmniPro-software.  
 
Figure 8. I’mRT Matrixx Evolution measurement set up. The array detector was 
placed on the gantry holder with SSD 100 cm and 5 cm of water equivalent 
build-up material was set above the detector.  
The measurement setup for I’mRT MatriXX Evolution is presented in the figure 8. The 
ionization chamber array was placed in the gantry holder with source to surface distance 
(SSD) of 100 cm for the measurements. 5 cm of water equivalent build-up material was 
placed above the detector. The array system underwent a 60-min warm up- time with 
power on and preirradiation with 800 MUs with 27 x 27 cm2 field size before the meas-
urements. After the preliminary irradiation, the background radiation was measured. The 
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calibration for absolute measurements were performed according to the manufacturer’s 
instructions. The calibration with 10 x 10 cm2 field size and 100 MU was based on the 
measurement values obtained from the four center chambers with reference doses of 
Dref(6FFF) = 0.914 Gy for 6 FFF and Dref(10FFF) = 0.982 Gy for 10 FFF beams.  
The treatment plans were irradiated in the QA mode of the linac and each arc was meas-
ured separately. The measurements were analyzed with OmniPro analysis software. The 
calculated dose distribution data was converted at first into measurement resolution of 
0.7619 cm, and then to the 0.1 cm resolution. The measured data was converted to the 
0.1 cm resolution. Synchronized rescaling with maximum dose to 100% was used. The 
alignment of the measured and calculated dose distributions was performed manually, 
as an automatic tool is not available in the software. 
4.6 Statistical methods 
The statistical tests were carried out using the IBM SPSS Statistics version 22.   
Normality of the data was tested with Shapiro-Wilk test as it is recommended test in the 
SPSS software for sample size of less than 50. (35) Tests for inferential statistics were 
chosen based on the normality test results (parametric or non-parametric tests).  
Correlations were obtained using Spearman’s Rho, as the most data sets were non-
normally distributed, according to the Shapiro-Wilk test. The Spearman’s Rho is a non-
parametric test used to measure the degree of association between two variables. The 
significance level of the correlation coefficient indicates the statistical significance of the 
coefficient. (36) 
In this thesis, the correlation is considered  
- weak, if the correlation coefficient is < 0.3 
- moderate, if the correlation coefficient is 0.3 - 0.7 
- strong, if the correlation coefficient is 0.7 - 0.9 
- very strong, if the correlation coefficient is > 0.9 
for statistically significant (p < 0.05) correlation coefficients.  
The independent samples tests used were the Mann-Whitney U Test (for 2 samples) and 
Kruskal-Wallis 1-way ANOVA (for 2-3 samples), as the most data sets were non-normally 
distributed, according to the Shapiro-Wilk test. Independent samples tests were used to 
evaluate the similarity of the distributions of two or three categories (36). Gamma passing 
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rates and average percentual dose differences in categories of brain/lung/prostate, 6 
FFF / 10FFF as well as PDIP/AAA/I’mRT MatriXX Evolution were compared.  
The paired samples test used was the Wilcoxon’s signed rank test, as the most data sets 
were non-normally distributed, according to the Shapiro-Wilk test. Wilcoxon’s signed 
rank test is a non-parametric analog to the pared Student’s t-test when the sample size 
is small and non-normally distributed. It determines whether two dependent samples are 
selected from the populations having the same distribution. (36) Gamma passing rates 
and average percentual dose differences were tested pairwise with Wilcoxon’s signed 
rank test between 6 FFF and 10 FFF, 5% threshold and 60% threshold, PDIP and AAA, 
PDIP and I’mRT MatriXX Evolution, as well as AAA and I’mRT MatriXX Evolution.  
Box plots for PTV volume, MU/Gy, gamma passing rates and average percentual dose 
differences were drawn. Thick line in the middle represents the median. The top and 
bottom boxes show the 75th and the 25th percentiles. Whiskers show the maximum and 
the minimum values, with the exceptions of outliers represented by circles and extremes 
represented by asterisks. (37) 
The p-value gives the probability that the two compared variables are from the same 
distribution with equal median. The significance level in this thesis was set to 0.05.  
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5. RESULTS 
5.1 Gamma analysis 
5.1.1 Portal dosimetry with PDIP-algorithm 
Results and statistics of portal dosimetry measurements with PDIP-algorithm for brain, 
lung and prostate tumors are presented in the following paragraphs. 
 
Figure 9. Box plot –distributions of gamma passing rates for portal dosimetry meas-
urements with PDIP-algorithm. Distributions are presented for brain, lung and 
prostate tumors with gamma criteria of 3%/3 mm (A), 2%/2 mm (B), 1%/1 mm 
(C) and 3%/1 mm (D). 
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Figure 9. presents the box plot distributions of gamma passing rates with gamma criteria 
of 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm for categories of brain, lung and prostate 
tumors.  According to the visual inspection of the distributions, the mean size of the target 
(brain 5.4 ± 4.3 cm3, lung 25.3 ± 18.6 cm3, prostate 84.8 ± 18.1 cm3) do not seem to have 
an predictable effect on gamma passing rates with gamma criteria of 3%/3 mm, 2%/2 
mm, 1%/1 mm. In case of gamma criteria of 3%/1 mm, the deviation decreases, as the 
mean target size increases. 
 
Figure 10. Box plot –distributions representing the effects of energy (6 FFF 
and 10 FFF) and threshold (5% and 60%) to gamma passing rates of portal do-
simetry measurements with PDIP-algorithm. Distributions are presented for 
brain, lung and prostate tumors with gamma criteria of 3%/3 mm (A), 2%/2 mm 
(B), 1%/1 mm (C) and 3%/1 mm (D). 
Figure 10. presents more detailed box plot -distributions of PDIP gamma analysis results 
with gamma analysis thresholds of 5% and 60%, and energies of 6 FFF and 10 FFF. 
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According to the visual inspection of the distributions, the gamma analysis results for 10 
FFF beams result in lower gamma passing rates and increased deviations. Also thresh-
old of 60% results in lower gamma passing rates and increased deviations, compared 
with threshold of 5%.  
Table 2. presents the descriptive statistics (mean, SD) and Independent-Samples Krus-
kal-Wallis Test results for brain, lung and prostate tumors. Visual observations can be 
supported by the descriptive statistics in the Table 2. Independent-Samples Kruskal-
Wallis tests reveal that as the gamma criteria tightens, significant differences between 
target site groups (brain, lung, prostate) increase. With gamma criterion of 3%/3 mm, 
only 6 FFF with 5% threshold reveals significant difference. With gamma criterion of 1%/1 
mm, 6 FFF with 5% or 60% thresholds and 10 FFF with 5% threshold reveal significant 
differences. Gamma criterion of 3%/1 mm reveals significant differences in all categories.     
 Descriptives and Independent-Samples Kruskal-Wallis Test results in categories of brain, 
lung and prostate tumors for portal dosimetry gamma passing rates with PDIP-algorithm. 
 
Brain Lung Prostate
Mean ± SD Mean ± SD Mean ± SD
6.08±4.28 23.22±18.48
4.18±3.70 28.18±17.83 84.80±17.56
267.4±50.7 339.9±82.0
253.53±16.74 296.15±40.59 303.79±18.29
Threshold
5 % 99.91±0.17 99.99±0.04
60 % 99.77±0.46 99.82±0.47
5 % 99.82±0.34 99.87±0.16 99.83±0.18
60 % 99.82±0.24 99.74±0.36 99.74±0.29
5 % 99.34±0.58 99.88±0.20
60 % 98.65±1.32 99.34±1.34
5 % 98.53±1.07 98.57±0.93 98.47±1.13
60 % 97.93±1.64 97.72±1.91 97.4±2.09
5 % 91.11±5.06 96.63±2.12
60 % 88.62±5.85 92.95±4.70
5 % 77.68±8.90 84.25±5.05 83.22±8.40
60 % 75.02±9.61 77.30±8.70 78.52±10.55
5 % 96.20±1.92 99.23±0.83
60 % 93.93±4.96 98.50±1.76
5 % 88.68±4.57 93.69±3.55 96.82±2.80
60 % 79.99±10.32 91.23±6.34 96.93±3.21
Independent-
Samples 
Kruskal-
Wallis Test 
(Sig.)
Independent-Samples Kruskal-Wallis Test null hypothesis: 
The distribution is the same across categories of Brain/Lung/Prostate.
0.000
0.000
0.000
0.016
0.047
0.567
0.000
0.000
0.713
0.535
0.000
0.007
0.982
0.732
0.239
0.002
0.000
0.029
0.000
0.000
10FFF
3%/3mm
2%/2mm
1%/1mm
6FFF
10FFF
6FFF
10FFF
3%/1mm
6FFF
10FFF
6FFF
Energy
MU/Gy
PTV volume 
(cm3)
6FFF
10FFF
6FFF
10FFF
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Table 3. presents Independent Samples Mann-Whitney U test results and correlations 
from energy comparison of treatment plans executed with 6 FFF or 10 FFF beam ener-
gies. Independent-Samples Mann-Whitney U Test reveals that in case of brain tumors, 
there is no significant difference between energies with gamma criteria of 3%/3 mm, but 
with tighter criteria, significant differences occur. In case of lung tumors, there are signif-
icant differences between energies with all gamma criteria. Portal dosimetry with PDIP-
algorithm results with higher gamma passing rates for 6 FFF beams compared to 10 FFF 
beams. Spearman’s correlations reveal that energy has a moderate correlation with 
gamma criteria of 2%/2 mm, 1%/1 mm and 3%/1 mm in case of brain tumors. In case of 
lung tumors, gamma criterion of 2%/2 mm correlate moderately, and gamma criteria of 
1%/1 mm and 3%/1 mm correlate strongly with energy.  
 Independent Samples Mann-Whitney U test results and correlations with energy for portal 
dosimetry gamma passing rates with PDIP-algorithm in categories of brain and lung tumors. 
  Brain Lung 
 
Independent-
Samples Mann-
Whitney U Test 
(Sig.) 
Correlations with 
energy: 
Spearman's Rho   
(Coef./Sig.) 
Independent-
Samples Mann-
Whitney U Test 
(Sig.) 
Correlations with 
energy: 
Spearman's Rho   
(Coef./Sig.) 
 
  
3%/3mm 0.115 -0.159/0.115 0.005 -0.323/0.004 
2%/2mm 0.001 -0.329/0.001 0.000 -0.645/0.000 
1%/1mm 0.000 -0.685/0.000 0.000 -0.803/0.000 
3%/1mm 0.000 -0.654/0.000 0.000 -0.727/0.000 
Independent-Samples Mann-Whitney U Test Null Hypothesis:                                                                                       
The distribution is the same across categories of 6FFF/10FFF. 
 
Table 4. presents results from Paired Samples Wilcoxon Signed Ranks tests and Spear-
man’s correlations for gamma passing rates with thresholds of 5% and 60%. The paired 
sample test results reveal that when comparing pairwise the results with 5% threshold 
and 60% threshold, significant differences occur. Brain tumors treated with 10 FFF do 
not reveal significant differences, but all the other tumor sites and energies reveal signif-
icant threshold dependency. Spearman’s correlations reveal that gamma passing rates 
with different thresholds correlate very strongly in brain 6 FFF 3%/3 mm, 6 FFF 2%/2 
mm, 6 FFF 3%/1 mm, as well as in  lung 10 FFF 3%/3 mm and 10 FFF 3%/3 mm. Gamma 
passing rates with different thresholds correlate strongly in brain 10 FFF 3%/3 mm, 10 
FFF 1%/1 mm, as well as in lung 10 FFF 3%/3 mm and 10 FFF 3%/1 mm. Gamma 
passing rates with different thresholds correlate moderately in brain 10 FFF 2%/2 mm, 6 
37 
 
FFF 1%/1 mm and 10 FFF 1%/1 mm, as well as in lung 6 FFF 2%/2 mm, 6 FFF 1%/1 
mm and 6 FFF 3%/1 mm. 
 
 Paired Sample Wilcoxon Signed Ranks test results and Spearman’s correlations for gamma 
analysis threshold comparisons for portal dosimetry with PDIP-algorithm. 
    Brain Lung Prostate 
  Wilcoxon 
Signed 
Ranks Test 
(5%PDIP vs. 
60%PDIP) 
(Sig.) 
Spearman's 
Rho  
(5%PDIP vs. 
60%PDIP) 
(Coef./Sig.) 
Wilcoxon 
Signed 
Ranks Test 
(5%PDIP vs. 
60%PDIP) 
(Sig.) 
 Spearman's 
Rho  
(5%PDIP vs. 
60%PDIP) 
(Coef./Sig.) 
Wilcoxon 
Signed 
Ranks Test 
(5%PDIP vs. 
60%PDIP) 
(Sig.) 
Spearman's 
Rho  
(5%PDIP vs. 
60%PDIP) 
(Coef./Sig.) 
  
    
3%/3mm 
6FFF 0.005 0.929/0.000 0.068 0.377/0.092     
10FFF 0.580 0.827/0.000 0.029 0.936/0.000 0.036 0.781/0.000 
2%/2mm 
6FFF 0.000 0.959/0.000 0.023 0.622/0.003     
10FFF 0.063 0.663/0.001 0.008 0.863/0.000 0.001 0.950/0.000 
1%/1mm 
6FFF 0.011 0.693/0.000 0.000 0.551/0.010     
10FFF 0.171 0.617/0.002 0.001 0.763/0.000 0.000 0.953/0.000 
3%/1mm 
6FFF 0.004 0.914/0.000 0.026 0.503/0.020     
10FFF 0.000 0.789/0.000 0.006 0.962/0.000 0.587 0.926/0.000 
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5.1.2 Portal dosimetry with AAA-algorithm 
Results and statistics applied by portal dosimetry with AAA-algorithm for brain and lung 
tumors are presented in the following paragraphs. 
 
 
Figure 11. Box plot –distributions of gamma passing rates for Portal dosimetry 
measurements with AAA-algorithm. Distributions are presented for brain and 
lung tumors with gamma criteria of 3%/3 mm (A), 2%/2 mm (B),1%/1 mm (C) 
and 3%/1 mm (D). 
Figure 11. presents the box plot distributions of gamma passing rates with gamma crite-
ria of 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm for categories of brain, lung and 
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prostate tumors. According to the visual inspection of the distributions, the mean size of 
the target (brain 5.4 ± 4.3 cm3, lung 25.3 ± 18.6 cm3) has a noticeable effect on gamma 
passing rates with all gamma criteria. The gamma passing rates seem to increase and 
deviations decrease, as the mean target size increases.  
 
Figure 12. Box plot –distributions representing the effect of threshold (5% and 
60%) to gamma passing rates of portal dosimetry measurements with AAA-al-
gorithm. Distributions are presented for brain and lung tumors with gamma crite-
ria of 3%/3 mm (A), 2%/2 mm (B),1%/1 mm (C) and 3%/1 mm (D). 
Figure 12. presents more detailed box plot distributions of AAA gamma analysis results 
with gamma analysis thresholds of 5% and 60%. According to the visual inspection of 
the distributions, the gamma analysis results with threshold of 60% results in lower 
gamma passing rates and increased deviations in comparison with the results with 
threshold of 5%.  
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Table 5. presents the descriptive statistics (mean, SD) and Independent-Samples Krus-
kal-Wallis Test results for brain, lung and prostate tumors. Visual observations about the 
effect of threshold can be supported by the descriptive statistics. Independent-Samples 
Kruskal-Wallis tests reveal significant differences between target site groups (brain, lung) 
in all the other categories but not in 60% 2%/2 mm or 60% 1%/1 mm.     
 Descriptives and Independent-Samples Kruskal-Wallis Test results in categories of brain, 
lung and prostate tumors for portal dosimetry gamma passing rates with AAA-algorithm. 
      Brain Lung 
Independent-
Samples  
Kruskal-Wallis 
Test   Energy Mean ± SD Mean ± SD 
PTV volume 
(cm3) 
 
6FFF 6.08±4.28 23.22±18.48 0.000 
MU/Gy 
 
6FFF 267.4±50.7 339.9±82.0 0.002 
The shortest   
distance to the 
skin surface (cm) 
 
 
 
6FFF 3.69±1.45 7.82±2.12 0.000 
  Threshold    
3%/3mm 6FFF 
5 % 99.18±0.76 99.57±0.68 0.012 
60 % 98.22±1.64 99.14±1.58 0.019 
2%/2mm 6FFF 
5 % 96.34±2.28 97.93±1.36 0.009 
60 % 94.33±3.68 95.90±2.82 0.173 
1%/1mm 6FFF 
5 % 67.23±11.49 80.04±7.03 0.000 
60 % 75.71±7.05 75.38±5.96 0.868 
3%/1mm 6FFF 
5 % 84.63±4.86 92.55±4.85 0.000 
60 % 81.61±7.25 89.37±7.57 0.002 
Independent-Samples Kruskal-Wallis Test null hypothesis:  
The distribution is the same across categories of Brain/Lung/Prostate. 
 
Table 6. presents results from Paired Sample Wilcoxon Signed Ranks tests and Spear-
man’s correlations for gamma passing rates with thresholds of 5% and 60%. The paired 
sample test results reveal that when comparing pairwise the results with 5% threshold 
and 60% threshold, significant differences occur for both tumor sites (except brain 1%/1 
mm). Spearman’s correlations reveal that gamma passing rates with different thresholds 
correlate very strongly in brain 3%/3 mm, lung 2%/2 mm and lung 3%/ 1mm, strongly in 
brain 2%/2 mm, lung 3%/3 mm and lung 1%/1 mm, as well as moderately in brain 3%/1 
mm. 
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 Paired Sample Wilcoxon Signed Ranks test results and Spearman’s correlations for gamma 
analysis threshold comparisons for portal dosimetry with AAA-algorithm 
    Brain Lung 
  Wilcoxon 
Signed Ranks 
Test (5%AAA 
vs. 60%AAA) 
(Sig.) 
Spearman's 
Rho  (5%AAA 
vs. 60%AAA) 
(Coef./Sig.) 
Wilcoxon 
Signed Ranks 
Test (5%AAA 
vs. 60%AAA) 
(Sig.) 
Spearman's 
Rho  (5%AAA 
vs. 60%AAA) 
(Coef./Sig.) 
  
    
3%/3mm 6FFF 0.000 0.910/0.000 0.015 0.872/0.000 
2%/2mm 6FFF 0.001 0.801/0.000 0.000 0.954/0.000 
1%/1mm 6FFF 0.001 0.224/0.262 0.001 0.776/0.000 
3%/1mm 6FFF 0.008 0.616/0.001 0.000 0.952/0.000 
 
  
42 
 
5.1.3 Comparison of PDIP and AAA algorithms in portal dosim-
etry 
Results and statistics applied by portal dosimetry with PDIP and AAA -algorithms for 
brain and lung tumors are presented in the following paragraphs.  
 
Figure 13. Box plot –distributions of gamma passing rates for portal dosimetry 
measurements with PDIP and AAA -algorithms for brain and lung tumors with 
gamma criteria of 3%/3 mm (A), 2%/2 mm (B),1%/1 mm (C) and 3%/1 mm (D). 
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Figure 13. presents the box plot distributions of gamma passing rates for portal dosimetry 
measurements with PDIP and AAA -algorithms for categories of brain and lung tumors 
with gamma criteria of 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm. According to the 
visual inspection of the distributions, the portal dosimetry algorithm has a noticeable ef-
fect on gamma passing rates with all gamma criteria. The gamma passing rates seem to 
be higher with PDIP algorithm than with AAA algorithm.  
Visual observations about the effect of algorithm can be supported by the Independent-
Samples Mann Whitney U test results revealing significant differences (p = 0.000) for all 
the gamma criteria between PDIP and AAA algorithms. 
Table 7. presents results from Paired Samples Wilcoxon Signed Ranks tests and statis-
tically significant (p > 0.05) Spearman’s correlations for gamma passing rates with PDIP 
and AAA algorithms. The paired sample test results reveal that when comparing pairwise 
the gamma passing rates with PDIP and AAA algorithms, significant differences occur in 
all the cases. Spearman’s correlations reveal that gamma passing rates with different 
algorithms correlate strongly in brain 60% 2%/2 mm and 3%/1 mm, as well as in lung 5% 
2%/2 mm, 5% 1%/1 mm and 5% 3%/1 mm. The gamma passing rates with different 
algorithms correlate moderately in brain 3%/3 mm, 5% 2%/2 mm and 5% 1%/1 mm, as 
well as in lung 60% 1%/1 mm and 60% 3%/1 mm.  
 
 Paired Sample Wilcoxon Signed Ranks test results and statistically significant (p > 0.05) 
Spearman’s correlations for portal dosimetry algorithm comparison (PDIP vs. AAA) in cate-
gories of brain and lung tumors. 
   Brain Lung 
    
Wilcoxon 
Signed 
Ranks Test 
(Sig.) 
Spearman's 
Rho 
(Coef./Sig.) 
Wilcoxon 
Signed 
Ranks 
Test (Sig.) 
Spearman's 
Rho 
(Coef./Sig.) 
3%/3mm 6FFF 
5 % 0.000 0.509/0.000 0.000  
60 % 0.000 0.584/0.001 0.004  
2%/2mm 6FFF 
5 % 0.000 0.614/0.001 0.000 0.701/0.000 
60 % 0.000 0.729/0.000 0.000   
1%/1mm 6FFF 
5 % 0.000 0.632/0.000 0.000 0.783/0.000 
60 % 0.000  0.000 0.588/0.005 
3%/1mm 6FFF 
5 % 0.000 0.731/0.000 0.000 0.898/0.000 
60 % 0.000 0.732/0.000 0.000 0.636/0.002 
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5.1.4 I’mRT MatriXX Evolution 
Results and statistics applied by array detector I’mRT MatriXX Evolution for brain, lung 
and prostate tumors are presented in the following paragraphs.  
 
Figure 14. Box plot –distributions of gamma passing rates for I’mRT MatriXX 
Evolution measurements. Distributions are presented for brain, lung and pros-
tate tumors with gamma criteria of 3%/3 mm (A), 2%/2 mm (B),1%/1 mm (C) 
and 3%/1 mm (D). 
 
Figure 14. presents the box plot distributions of gamma passing rates with gamma crite-
ria of 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm for categories of brain, lung and 
prostate tumors.  According to the visual inspection of the distributions, the mean size of 
the target (brain 5.4 ± 4.3 cm3, lung 25.3 ± 18.6 cm3, prostate 84.8 ± 18.1 cm3) seems to 
have an predictable effect on gamma passing rates. In case of gamma criteria of 3%/3 
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mm, 2%/2 mm and 3%/1 mm, the median gamma passing rates increase and the devi-
ations decrease, as the mean target size increases. In case of gamma criteria of 1%/1 
mm, the deviation decreases, as the mean target size increases, but no significant effect 
on median gamma passing rates can be seen.  
 
Figure 15. Box plot –distributions representing the effects of energy (6 FFF 
and 10 FFF) and threshold (5% and 60%) to gamma passing rates of I’mRT 
MatriXX Evolution -measurements. Distributions are presented for brain and 
lung tumors with gamma criteria of 3%/3 mm (A), 2%/2 mm (B),1%/1 mm (C) 
and 3%/1 mm (D). 
Figure 15. presents more detailed distributions of I’mRT MatriXX Evolution gamma anal-
ysis results with gamma analysis thresholds of 5% and 60%, and energies of 6 FFF and 
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10 FFF. According to the visual inspection of the distributions, the gamma analysis re-
sults for 10 FFF beams result in lower gamma passing rates and increased deviations in 
comparison with 6 FFF for brain tumors. In case of lung tumors, the gamma analysis 
results for 6 FFF beams result in lower gamma passing rates compared to the 10 FFF.  
The threshold of 60% results in higher gamma passing rates and increased deviations 
compared to the threshold of 5%.  
Table 8. presents the descriptive statistics (mean, SD) and Independent-Samples Krus-
kal-Wallis Test results for brain, lung and prostate tumors. Visual observations can be 
supported by the descriptive statistics. Independent-Samples Kruskal-Wallis tests reveal 
that gamma passing rates with 6 FFF (brain vs. lung) do not differ significantly, but in 
case of 10 FFF (brain, lung, prostate), significant differences occur between target site 
groups. 
 Descriptives and Independent-Samples Kruskal-Wallis test results for I’mRT MatriXX Evolu-
tion measurement results in categories of brain, lung and prostate tumors. 
      Brain Lung Prostate 
Independent- 
Samples Kruskal-
Wallis Test   Energy Mean ± SD Mean ± SD Mean ± SD 
PTV  
volume (cm3) 
6FFF 6.08±4.28 23.22±18.48  0.000 
10FFF 4.18±3.70 28.18±17.83 84.80±17.56 0.000 
MU/Gy 
6FFF 267.4±50.7 339.9±82.0  0.002 
10FFF 253.53±16.74 296.15±40.59 303.79±18.29 0.000 
  Threshold      
3%/3mm 
6FFF 
5 % 97.60±1.90 98.23±0.96   0.400 
60 % 96.25±3.00 97.19±1.42  0.383 
10FFF 
5 % 97.40±1.90 99.10±0.83 99.48±0.38 0.000 
60 % 97.49±1.89 98.06±1.77 98.84±0.93 0.057 
2%/2mm 
6FFF 
5 % 88.86±4.18 89.19±4.61   0.678 
60 % 88.92±4.47 88.82±3.37  0.876 
10FFF 
5 % 85.26±5.25 93.49±2.64 96.25±1.22 0.000 
60 % 90.45±5.04 92.95±3.82 95.22±1.93 0.003 
1%/1mm 
6FFF 
5 % 45.05±6.05 40.53±4.78   0.020 
60 % 64.59±12.63 58.02±8.81  0.090 
10FFF 
5 % 39.26±8.76 42.02±6.95 44.56±4.86 0.141 
60 % 68.51±14.84 59.65±10.46 54.83±4.66 0.000 
3%/1mm 
6FFF 
5 % 73.09±5.84 71.46±8.42   0.625 
60 % 77.04±7.53 76.56±5.23  0.633 
10FFF 
5 % 64.65±6.16 77.73±6.52 85.44±2.93 0.000 
60 % 77.66±11.10 83.68±4.94 88.60±3.00 0.000 
  Independent-Samples Kruskal-Wallis Test null hypothesis: 
  The distribution is the same across categories of Brain/Lung/Prostate. 
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Table 9. presents Independent Samples Mann-Whitney U test results and correlations 
from energy comparison of treatment plans executed with 6 FFF or 10 FFF beams. In-
dependent-Samples Mann-Whitney U Test reveals that brain tumors do not show energy 
dependency (p > 0.05), but lung tumors show significant energy dependency for 3%/3 
mm, 2%/2 mm and 3%/1 mm. Spearman’s correlations reveal that energy do not show 
correlation for brain tumors, but lung tumors exhibit a moderate correlation with gamma 
passing criteria 3%/3 mm, 2%/2 mm and 3%/1 mm.  
 
 Independent Samples Kruskal-Wallis test results and correlations for I’mRT MatriXX Evolu-
tion measurements in categories of 6 FFF and 10 FFF 
  Brain Lung 
 Independent-
Samples Mann-
Whitney U Test 
(Sig.) 
Correlations 
with energy: 
Spearman's 
Rho   
(Coef./Sig.) 
Independent-
Samples Mann-
Whitney U Test 
(Sig.) 
Correlations 
with energy: 
Spearman's Rho   
(Coef./Sig.) 
 
  
3%/3mm 0.536 0.062/0.539 0.001 0.370/0.001 
2%/2mm 0.538 -0.062/0.541 0.000 0.511/0.000 
1%/1mm 0.619 -0.050/0.621 0.541 0.070/0.544 
3%/1mm 0.058 -0.190/0.058 0.000 0.433/0.000 
Independent-Samples Mann-Whitney U Test Null Hypothesis:                                                                                       
The distribution is the same across categories of 6FFF/10FFF. 
 
Table 10. presents results from Paired Sample Wilcoxon Signed Ranks tests and Spear-
man’s correlations for 5% and 60% gamma analysis thresholds. The paired sample test 
results reveal that when comparing the results with 5% threshold and 60% threshold, 
significant differences occur in all other cases except 10 FFF 3%/3 mm for brain tumors, 
6 FFF 1%/1 mm for lung tumors and 6 FFF 2%/2 mm for brain and lung tumors. Spear-
man’s correlations reveal that gamma passing rates with different thresholds correlate 
very strongly in brain 6 FFF 3%/3 mm and lung 6 FFF 3%/3 mm. The gamma passing 
rates with different thresholds correlate strongly in brain 10 FFF 3%/3 mm, 6 FFF 2%/2 
mm, 10 FFF 2%/2 mm, 6 FFF 1%/1 mm and 10 FFF 1%/1 mm, as well as in lung 10FFF 
3%/3mm. The gamma passing rates with different thresholds correlate moderately in 
lung 6 FFF 2%/2 mm, 10 FFF 1%/1 mm and 6 FFF 3%/1 mm. 
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 Paired sample Wilcoxon Signed Ranks test results and Spearman’s correlations for I’mRT 
MatriXX Evolution in categories of brain, lung and prostate tumors. 
    Brain Lung Prostate 
  
Wilcoxon 
Signed Ranks 
Test (5%MA-
TRIX vs. 
60%MATRIX) 
(Sig.) 
Spearman's 
Rho  (5%MA-
TRIX vs. 
60%MATRIX) 
(Coef./Sig.) 
Wilcoxon 
Signed Ranks 
Test (5%MA-
TRIX vs. 
60%MATRIX) 
(Sig.) 
Spearman's 
Rho  (5%MA-
TRIX vs. 
60%MATRIX) 
(Coef./Sig.) 
Wilcoxon 
Signed Ranks 
Test (5%MA-
TRIX vs. 
60%MATRIX) 
(Sig.) 
Spearman's 
Rho  (5%MA-
TRIX vs. 
60%MATRIX) 
(Coef./Sig.) 
  
    
3%/3mm 
6FFF 0.000 0.905/0.000 0.000 0.742/0.000     
10FFF 0.939 0.801/0.000 0.000 0.909/0.000 0.000 0.971/0.000 
2%/2mm 
6FFF 0.801 0.811/0.000 0.509 0.649/0.001     
10FFF 0.000 0.701/0.000 0.943 0.536/0.022 0.000 0.967/0.000 
1%/1mm 
6FFF 0.000 0.897/0.000 0.000 0.310/0.171     
10FFF 0.000 0.713/0.000 0.000 0.618/0.006 0.000 0.808/0.000 
3%/1mm 
6FFF 0.008 0.465/0.017 0.012 0.455/0.038     
10FFF 0.001 0.448/0.032 0.005 0.405/0.095 0.001 0.631/0.005 
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5.1.5 Comparison of Portal dosimetry and I’mRT MatriXX Evo-
lution 
 
Results and statistics applied by portal dosimetry with PDIP and AAA-algorithms as well 
as array detector I’mRT MatriXX Evolution for brain, lung and prostate tumors are pre-
sented in the following paragraphs.  
 
Figure 16. Box plot –distributions of gamma passing rates for portal dosimetry 
measurements with PDIP and AAA –algorithms and I’mRT MatriXX Evolution 
measurement for brain, lung and prostate tumors with gamma criteria of 3%/3 
mm (A), 2%/2 mm (B),1%/1 mm (C) and 3%/1 mm (D). 
 
Figure 16. presents the box plot -distributions of gamma passing rates with gamma cri-
teria of 3%/3 mm, 2%/2 mm, 1%/1 mm and 3%/1 mm for categories of brain, lung and 
prostate tumors.  According to the visual inspection of the distributions, the measurement 
50 
 
method (portal dosimetry with PDIP or AAA algorithms, or I’mRT MatriXX Evolution) has 
a significant visual effect on gamma passing rates with the all gamma criteria. The 
gamma passing rates decrease and the deviations increase from PDIP to AAA and AAA 
to I’mRT MatriXX Evolution.  
Independent-Samples Kruskal-Wallis Tests for brain, lung and prostate tumors in cate-
gories of PDIP/AAA/I’mRT MatriXX Evolution reveal that gamma passing rates differ sig-
nificantly (p = 0.000) for all the target sites between categories PDIP, AAA and I’mRT 
MatriXX Evolution.  
Table 11. presents statistically significant results from Paired Sample Wilcoxon Signed 
Ranks tests and statistically significant Spearman’s correlations for 6 FFF and 10 FFF 
energies, and 5% and 60% gamma analysis thresholds. Paired Sample Wilcoxon Signed 
Rank tests reveal that gamma passing rates with PDIP differ significantly from gamma 
passing rates with I’mRT MatriXX Evolution and the gamma passing rates with AAA differ 
significantly from the gamma passing rates with I’mRT MatriXX Evolution.  
I’mRT MatriXX Evolution results do not correlate with PDIP or AAA (except moderate 
correlations in PDIP 10 FFF 3%/3 mm, 10 FFF 5% 2%/2 mm, 10 FFF 5% 1%/1 mm and 
10 FFF 60% 3%/1 mm, as well as in AAA 60% 1%/1 mm).  
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 Statistically significant results from Paired Sample Wilcoxon Signed Ranks tests and statisti-
cally significant Spearman’s correlations for 6FFF and 10FFF energies, and 5% and 60% 
gamma analysis thresholds. 
        Brain Lung Prostate 
      
Wilcoxon 
Signed 
Ranks 
Test (Sig.) 
Spearman's 
Rho 
(Coef./Sig.) 
Wilcoxon 
Signed 
Ranks 
Test (Sig.) 
Spearman's 
Rho 
(Coef./Sig.) 
Wilcoxon 
Signed 
Ranks Test 
(Sig.) 
Spearman's 
Rho 
(Coef./Sig.) 
PDIP vs. 
I'mRT 
MatriXX 
Evolu-
tion 
3%/3mm 
6FFF 
5 % 0.000   0.000       
60 % 0.000  0.000    
10FFF 
5 % 0.000  0.000 0.556/0.017 0.004  
60 % 0.000   0.000 0.490/0.039 0.001   
2%/2mm 
6FFF 
5 % 0.000  0.000    
60 % 0.000  0.000    
10FFF 
5 % 0.000  0.000 0.481/0.043 0.000  
60 % 0.000  0.000  0.005  
1%/1mm 
6FFF 
5 % 0.000   0.000       
60 % 0.000  0.000    
10FFF 
5 % 0.000  0.000 0.494/0.037 0.000  
60 % 0.287   0.000   0.000   
3%/1mm 
6FFF 
5 % 0.000  0.000    
60 % 0.000  0.000    
10FFF 
5 % 0.000  0.000  0.000  
60 % 0.715   0.001 0.606/0.008 0.000   
AAA vs. 
I'mRT 
MatriXX 
Evolu-
tion 
3%/3mm 6FFF 
5 % 0.001   0.000       
60 % 0.004  0.001    
2%/2mm 6FFF 
5 % 0.000   0.000       
60 % 0.000   0.000       
1%/1mm 6FFF 
5 % 0.000  0.000    
60 % 0.000 0.493/0.009 0.000    
3%/1mm 6FFF 
5 % 0.000   0.000       
60 % 0.000   0.000       
 
Table 12. presents comparison of gamma passing rate pass/fail threshold result of > 
95% (x), 95% > γ > 90% (o), 90% > γ (-). PDIP results of 3%/3 mm and 2%/2 mm fulfil 
the gamma pass threshold of > 95%. PDIP results of 3%/1mm fulfil the gamma pass 
threshold of > 90%, except in case of brain 10FFF. AAA results of 3%/3 mm fulfil the 
gamma pass threshold of > 95% and results of 2%/2 mm fulfil the gamma pass threshold 
of > 90%. I’mRT MatriXX Evolution results of 3%/3 mm fulfil the gamma pass threshold 
of > 95%. 
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 Comparison of gamma passing rate pass/fail result of >95% (x), 95%>γ>90% (o),          
90%>γ (-). 
      PDIP AAA MatriXX 
      Brain Lung Prostate Brain Lung Brain Lung Prostate 
3%/3mm 
6FFF 
5 % x x  x x x x  
60 % x x  x x x x  
10FFF 
5 % x x x     x x x 
60 % x x x     x x x 
2%/2mm 
6FFF 
5 % x x   x x _ _   
60 % x x  o x _ _  
10FFF 
5 % x x x     _ o x 
60 % x x x     o o x 
1%/1mm 
6FFF 
5 % o x   _ _ _ _   
60 % _ o  _ _ _ _  
10FFF 
5 % _ _ _     _ _ _ 
60 % _ _ _     _ _ _ 
3%/1mm 
6FFF 
5 % x x   _ o _ _   
60 % o x  _ _ _ _  
10FFF 
5 % _ o x     _ _ _ 
60 % _ o x     _ _ _ 
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5.2 Average percentual dose difference 
Average percentual dose difference results and statistics applied by portal dosimetry with 
PDIP and AAA-algorithms for brain, lung and prostate tumors are presented in the fol-
lowing paragraphs.  
 
 
Figure 17. The box plot distributions of average percentual dose differences 
(Avg/Max)  between measured and predicted doses for portal dosimetry with 
PDIP and AAA –algorithms in categories of brain, lung and prostate tumors. 
 
Figure 17. presents the box plot distributions of average percentual dose differences 
between measured and predicted doses for portal dosimetry with PDIP and AAA –algo-
rithms. According to the visual inspection of the distributions, the mean size of the target 
(brain 5.4 ± 4.3 cm3, lung 25.3 ± 18.6 cm3, prostate 84.8 ± 18.1 cm3) seems to have an 
effect on average percentual dose difference on both portal dosimetry algorithms. The 
average percentual dose difference decreases. In case of PDIP –algorithm, the deviation 
decreases, as the mean target size increases. Table 13. presents the descriptive statis-
tics (mean, SD) and Independent-Samples Kruskal-Wallis Test results for brain, lung and 
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prostate targets. Visual observations can be supported by the descriptive statistics. In-
dependent-Samples Kruskal-Wallis tests reveal that the average percentual dose differ-
ences with PDIP or AAA-algorithms differ significantly between target site groups. 
 
 Decsriptives and Independent samples Kruskal-Wallis test results in categories 
Brain/Lung/Prostate 
        Brain Lung Prostate Independent-
Samples Kruskal-
Wallis Test     Energy Threshold Mean ± SD Mean ± SD Mean ± SD 
Avg/Max 
PDIP 
6FFF 
5 % -2.68±0.43 -1.96±0.53   0.000 
60 % -3.27±1.25 -2.07±0.67  0.000 
AAA 
5 % -3.55±0.34 -3.07±0.53  0.001 
60 % -4.07±1.09 -2.77±0.87   0.000 
 
PDIP 10FFF 
5 % -4.08±0.54 -2.99±0.43 -2.25±0.52 0.000 
 60 % -6.51±2.50 -3.10±0.69 -1.93±0.44 0.000 
Independent-Samples Kruskal-Wallis Test null hypothesis:  
The distribution is the same across categories of Brain/Lung/Prostate. 
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Figure 18. The box plot -distributions of average percentual dose difference 
(Avg/Max) for gamma analysis thresholds of 5% and 60% for PDIP and AAA –
algorithms and 6 FFF and 10 FFF energies  
Figure 18. presents the box plot -distributions of average percentual dose difference for 
gamma analysis thresholds of 5% and 60% for PDIP and AAA –algorithms and 6 FFF 
and 10 FFF energies. According to the visual inspection, the average percentual dose 
difference increases and the deviation increases as the the energy increases from 6FFF 
to 10FFF. The effect of energy can be seen in both tumor sites (brain and lung), but is 
more pronounced in brain tumors. The average percentual dose difference increases 
and the deviation increases with the threshold of 60% in comparison with the threshold 
of 5%. 
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Table 14. presents the independent samples tests, paired samples tests and correlations 
for average percentual dose difference. Independent-Samples Mann-Whitney U Test re-
veals that average percentual dose difference in brain metastases and lung tumors show 
significant energy dependency. The paired sample test results reveal that when compar-
ing the results with 5% threshold and 60% threshold, significant differences occur in 
PDIP-results for brain, AAA-results for lung and PDIP-results for prostate. Spearman’s 
correlations reveal that the average percentual dose difference values correlate very 
strongly in lung PDIP 10FFF. The average percentual dose difference values correlate 
strongly in brain PDIP 6FFF, and in lung PDIP 6FFF, lung AAA 6FFF, as well as in pros-
tate PDIP. The average percentual dose difference values correlate moderately in brain 
PDIP 10FFF.    
 Independent samples tests, paired samples tests and correlations for average percentual 
dose difference (Avg/Max) 
    Brain Lung Prostate 
  
Independent-Samples Kruskal-Wallis Test (Sig.)                                                                                                                                             
Null Hypothesis: The distribution is the same across cate-
gories of PDIP/AAA   
Avg/Max 0.000 0.000   
  Independent-Samples Mann-Whitney U Test (Sig.)                                                     
Null Hypothesis: The distribution is the same across cate-
gories of PDIP 6FFF/10FFF. 
    
    
Avg/Max 
6FFF 
 0.000 0.000 
  
10FFF   
  Paired Samples: Wilcoxon Signed Ranks Test (Sig.) 
    
 5%PDIP vs. 
60%PDIP 
5%AAA vs. 
60%AAA 
 5%PDIP vs. 
60%PDIP 
5%AAA vs. 
60%AAA 
5%PDIP vs. 60%PDIP 
Avg/Max 
6FFF 0.002 0.074 0.498 0.015   
10FFF 0.000  0.286  0.000 
    Correlations: Spearman's Rho (Coef./Sig.) 
    
 5%PDIP vs. 
60%PDIP 
5%AAA vs. 
60%AAA 
 5%PDIP vs. 
60%PDIP 
5%AAA vs. 
60%AAA 
5%PDIP vs. 60%PDIP 
Avg/Max 
6FFF 0.796/0.000 0.125/0.534 0.788/0.000 0.826/0.000   
10FFF 0.522/0.011   0.901/0.000   0.858/0.000 
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6. DISCUSSION 
The utilization of VMAT-technique in stereotactic treatments has rapidly increased. 
Treatments executed with VMAT-technique are comprised of small fields and even 
smaller subfields. The small field size induces different kinds of dosimetric challenges. 
Dosimetric challenges include detector size, steep dose gradient, loss of charged particle 
equilibrium, volume averaging effect and partial occlusion of the primary photon source 
by the collimating devices. In addition, small field size induces also dosimetric challenges 
due to small MLC apertures, high transmission, DLG and tongue and groove effects, as 
well as their effects on dose calculation. The small target volumes challenge the different 
measurement methods in varying amount. 
IMRT/VMAT techniques have enabled higher conformal radiation doses in the tumor, 
compared to the conventional techniques, and sparing of normal tissues surrounding the 
tumor site. These advanced radiation therapy techniques have increased the accuracy 
requirements for dose delivery. With stereotactic high dose treatments, the importance 
of the quality assurance of treatment plans is highlighted and the dosimetric perfor-
mances of measurement devices need to be carefully assessed.  
The quality assurance of treatment plans is an important part of execution of stereotactic 
treatments. In daily practice, the effortlessness and speed of these procedures are im-
portant factors when selecting the appropriate measurement method.  
Previously the film measurements have been considered as the gold standard for quality 
assurance of treatment plans, as it is the oldest method and has an extremely high spa-
tial resolution. However, the radiochromic film has significant disadvantages. The cali-
bration curve is determined by irradiating pieces of the film with known different doses, 
separately for each experiment. The calibration film and the measurement film are irra-
diated on the same day, and the scanning of those is carried out on the same day and 
in the same orientation respect to the original orientation, but a waiting period between 
the irradiation and scanning is required to guarantee the stabilization of the film darken-
ing. The storage conditions of the films and time between the irradiation and scanning 
are required to be constant. The radiochromic films exhibit significant variation in optical 
density when the light source is linearly polarized, so the orientation of the film in the 
scanner is crucial. In conclusion, for practical purposes, reliable film dosimetry protocols 
are too laborious to establish.  
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For measurements using sparse array detectors, interpolation to a finer resolution and 
resampling of the dose distribution to the configuration of the detector array will be re-
quired. These processes can introduce uncertainties for the measurement results. 
The advances of the portal dosimetry are fast image acquisition, high resolution and 
digital format. However, the dose is modelled in the ideal portal detector plate, but the 
response might change in time and might be individual for each detector plate. The PDIP 
calculation can be re-configured time by time to take into account the change in the re-
sponse. The AAA calculation model do not take into account these variations and the 
significance of this effect is difficult to estimate.  
A shortage of this thesis is fixed positions of both measurement devices in the gantry 
geometry. The effects of couch rotations cannot be measured and true 3D dose distribu-
tion stays unknown. Statistical tests evaluate the stochastic errors of the methods, but 
they cannot evaluate the systematic errors of the methods. The amount of data is quite 
small in this thesis, so the results include uncertainty in some amount. In case of small 
stereotactic targets, the exact placement of measurement device in the radiation field 
might cause systematic errors in the results, especially in case of detector arrays.   
With all the measurement methods, the “truth” stays unclear, as all the different meas-
urement methods have limitations. The importance of optimization of DLG has been re-
ported in literature (18, 19, 38-40). Kielar et al. (18) investigated the rounded leaf effect 
on the HD120™ MLC of Varian TrueBeam™ STx linac. DLG value was determined using 
MLC-defined field sizes and moving gap test. After that they optimized the DLG-value in 
the Eclipse treatment planning system to achieve less than 1% difference between 
measured and calculated dose. The optimized DLG value was tested on treatment plans 
for all energies and treatment modalities available on the linac with ionization chamber 
and film measurements. They found that the DLG parameter found during the initial MLC 
testing did not match the leaf gap modelling parameter that provided the most accurate 
dose delivery in clinical treatment plans. 
The tuning of the DLG could make the measurement distributions to agree well with the 
predicted distribution, but the exact truth about the ability of the treatment machine to 
deliver the given treatment plan remains still a bit uncertain. The tuning of the DLG af-
fects both the measured dose distribution and the predicted dose distribution, so the 
effects might not be straightforward.  
The aim of this study was to quantitatively compare measurement methods for QA of 
stereotactic treatment plans. Portal dosimetry measurements with PDIP and AAA -algo-
rithms were compared with array detector measurements with I’mRT MatriXX Evolution. 
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The both measurement devices were dose calibrated before measurements according 
to the manufacturer recommended protocols. Principled errors related to the absolute 
dose calibration should not occur, but target size dependent errors might occur. It is of 
outmost importance to know the differences between different measurement methods. 
This thesis gives quantitative information for QA of stereotactic treatment plans from por-
tal dosimetry with PDIP and AAA dose calculation algorithms, and I’mRT MatriXX Evo-
lution array detector with constant study material.  
In this thesis, the PDIP results showed that the target volume has a weak effect on 
gamma passing rates, being most pronounced on gamma criterion 3%/1mm. Gamma 
passing rates increase  as the target volume increases.  
PDIP results also showed an energy dependency, especially with tighter gamma criteria. 
PDIP measurements result in higher gamma passing rates for treatment plans with 6 
FFF beam than 10 FFF beams.  
Xu et al. (41) investigated the dose rate response characteristics of the Varian aS1200-
detector. The IMRT dose rate study for gamma index analysis showed that the gamma 
index agreement decreased when the dose rate increased. For 6 FFF fields, the gamma 
index agreement decreased from 100% to 97.8% with dose rate increasing from 400 to 
1400 MU/min. For 10 FFF fields, the gamma index agreement decreased from 99.9% to 
91.5% whit dose rate increasing from 400 to 2400 MU/min. The open field measurement 
showed only about 1% increase in central portal dose from 400 to 2400 MU/min. Based 
on these results, Xu et al. discussed that the decrease in the gamma agreement index 
is mainly due to the challenges caused by the high dose rate to the MLC motion. (41) 
The findings by Xu et al. might explain the energy dependency of our PDIP results. On 
the other hand, their discussion about the reasons for the energy dependency (chal-
lenges of the MLC with high dose rate) does not explain why PDIP results and I’mRT 
MatriXX Evolution results differ. The backscatter might affect the results with 10 FFF, 
although the aS1200 detector has an improved backscatter shielding.   
Energy comparison (6 FFF vs. 10 FFF) of average percentual dose difference results 
with PDIP showed that the energy dependency occurs on both tumor groups (brain and 
lung) but is more pronounced on brain tumors. The average percentual dose difference 
increases and the deviation increases as the energy increases from 6 FFF to 10 FFF.  
Average percentual dose difference results showed that the mean size of the target has 
an effect on the average percentual dose difference results. The average percentual 
dose difference decreases and the deviation decreases, as the mean target size in-
creases. 
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Covington et al. (7) assessed the feasibility of single target 10 FFF SRS QA with portal 
dosimetry, delivered with Varian Edge linear accelerator equipped with HDMLC and 
aS1200 portal dose imager. The average measured portal image to PDIP predicted im-
age dose was 0.992 ± 0.02, indicating that the measured dose was smaller than the 
predicted dose. The average film to treatment planning system dose in the high dose 
region was 1.026 ± 0.01. When they compared the mean dose in the film with the mean 
dose in the portal image, they found target size dependence: with target diameters 
greater than 15 mm, the ratio was 1.03, with target diameters of less than 15 mm the 
ratio was 1.05, with the smallest diameters, the ratio was 1.08. They also studied the 
dose rate effect on portal imaging results and the lowest dose rate of 400 MU/min re-
sulted in the greatest agreement with the predicted image and the clinically used dose 
rate of 2400 MU/min showed an increased difference at smaller field sizes. They con-
clude that the portal dosimetry measurement results were target size dependent and 
could deviate up to 8% from film measurements for the smallest target. (7) 
The findings by Covington et al. support the findings of this study about the fact that the 
measured doses are smaller than the predicted doses, and are target size dependent.  
I’mRT MatriXX Evolution results showed that the target volume has a strong effect on 
gamma passing rates. Gamma passing rates increase and deviations decrease as the 
target volume increases. I’mRT MatriXX Evolution results also showed an energy de-
pendency for lung tumors, especially with tighter gamma criteria. I’mRT MatriXX Evolu-
tion lung tumor results with higher gamma passing rates for treatment plans with 10 FFF 
beam than 6 FFF beams. On the other hand, brain tumors do not show energy depend-
ency. The sparse spatial resolution of I’mRT MatriXX Evolution array detector probably 
explains the target volume dependency. The energy dependency might result from the 
backscatter, sensitivity of the array detector to different energies or the uncertainties in 
the dose calculations. Mean energy of the 6 FFF beam might be too low for the array to 
work properly.  
Chung et al. (6) compared the performance of different commercial QA systems for pre-
treatment QA of SBRT treatment plans (lung, spine and prostate tumors) with VMAT and 
FFF-beams. QA systems tested were a film, I’mRT MatriXX and MapCHECK. Gamma 
evaluation with gamma criteria of 2%/2 mm and 3%/3 mm was analyzed. The highest 
gamma passing rates were obtained with MapCHECK and lowest gamma passing rates 
were obtained with film. Gamma passing rates with I’mRT MatriXX were 93.6% for 
gamma criterion 2%/2 mm and 98.2% for gamma criterion of 3%/3 mm.  Gamma passing 
rates with I’mRT MatriXX for 6 FFF were 93.8% ± 1.8% for 2%/2 mm and 98.0% ± 1.3% 
for 3%/3 mm. Gamma passing rates for 10 FFF were 93.4% ± 1.7% for 2%/2 mm and 
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98.3% ± 1.5% for 3%/3 mm. Gamma passing rates agree well with gamma passing rates 
obtained in this these with I’mRT MatriXX Evolution for treatment plans of lung and pros-
tate tumors, but results in this thesis show more pronounced effect of beam energy to 
gamma passing rates.  
Result comparison of PDIP, AAA and I’mRT MatriXX Evolution measurements reveal 
that the measurement method has a significant effect on gamma passing rates with all 
gamma criteria. The gamma passing rates decrease and the deviation increase from 
PDIP to AAA and AAA to I’mRT MatriXX Evolution. PDIP results correlate with AAA re-
sults, but I’mRT MatriXX Evolution results do not correlate with PDIP or AAA results. 
These results can be probably explained by the resolutions of the measurement devices. 
The comparison of PDIP and AAA –algorithms in portal dosimetry reveals, that the meas-
urements with PDIP-calculations result in higher gamma passing rates than with AAA-
calculations. No articles about the comparison of portal dosimetry results with PDIP and 
AAA algorithms were found in the literature, as the AAA as a portal prediction algorithm 
is quite new option.  
The reliability of the gamma index analysis in detecting clinically significant errors has 
been questioned in the literature. Nelms et al. (29) investigated the IMRT QA rates and 
clinically relevant dose errors. They questioned the power of standard acceptance crite-
ria to predict the clinically relevant patient dose errors and the certainty to which abiding 
the standards mitigates risk of significant error. They introduced the scenarios of “false 
positive” and “false negative”. “False positive” stands for the case in which the beam-by-
beam QA results fail to meet criteria, although the clinical impact can be considered 
negligible. “False negative” stands for the case in which beam-by-beam QA results meet 
the criteria, but still relevant and actionable patient dose errors occur. They conclude that 
in both scenarios, the magnitude and location of the errors may prove to be more critical 
than the quantity of the errors described by the passing rates per field and the gamma 
passing rates are not sensitive to clinically relevant patient dose errors on a per-patient 
basis. Meeting the Gamma passing rate criteria does not guarantee that clinically ac-
ceptable dose errors are within tolerance per patient, neither not meeting gamma pass-
ing rates does not imply that clinically relevant dose differences would be significant. 
However, the gamma index analysis has been widely accepted method, and it is imple-
mented into most analysis software of commercial measurement devices. The ad-
vantage of gamma index tool is that it is an efficient tool in the busy clinical environment. 
The understanding of the limitations and sensitivity of the gamma index analysis in case 
of a particular measurement device is important, as the same passing criteria will end up 
with different results, depending on the particular measurement device. As shown in this 
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thesis, the same passing criteria do not give the same results for measurements with 
different measurement devices. 
In clinical QA routine, the gamma passing rate is calculated and a pass/fail threshold is 
set to determine whether the treatment plan pass or fail the quality assurance measure-
ment, i.e. whether the treatment plan is clinically acceptable or not. The gamma criterion 
of 3%/3 mm is commonly used in the gamma analysis of treatment plans, but might be 
too loose criterion for stereotactic plans with narrow PTV margins. The gamma criterion 
of 1%/1 mm is very tight criterion, taking into account the resolution of different meas-
urement methods. The gamma criterion 3%/1mm might be considered appropriate for 
stereotactic treatment plans, as it gives an opportunity to examine the geometrical accu-
racy of the dose delivery, allowing 3% variation in the dose level due to the measurement 
method, treatment planning system and treatment machine based inaccuracies.  
A common passing threshold for 3%/3 mm is 95%, meaning that the treatment plan is 
clinically acceptable, if the gamma passing rate is higher than 95%. With tighter gamma 
criteria (i.e. 3%/1 mm), looser gamma passing threshold, for example 90% might be more 
reasonable, depending on the measurement method. On the other hand, for stereotactic 
treatment plans, high accuracy is required.  
The results in passing or failing the gamma pass threshold (table 12.) showed that for 
portal dosimetry measurements with PDIP algorithm, results with gamma analysis crite-
ria 3%/3 mm and 2%/2 mm pass the gamma pass threshold of 95%. PDIP results with 
gamma analysis criteria 3%/1 mm pass the gamma pass threshold of 90% in all other 
cases but 10 FFF brain tumors, i.e. the smallest targets with 10 FFF beams. For portal 
dosimetry measurements with AAA algorithm, results with gamma analysis criterion 
3%/3 mm pass the gamma pass threshold of 95% and results with gamma analysis cri-
terion 2%/2 mm pass the gamma pass threshold of 90%. For I’mRT MatriXX Evolution 
measurements, results with gamma analysis criterion 3%/3 mm pass the gamma pass 
threshold of 95% and results with gamma analysis criterion 2%/2 mm pass the gamma 
pass threshold of 90% for 10 FFF energy, except brain 5%.  Results with gamma analysis 
criterion 2%/2 mm for 6 FFF and tighter gamma criteria fail the both gamma pass thresh-
olds. In conclusion, the portal dosimetry measurements with PDIP and AAA –algorithms, 
as well as array detector measurement with I’mRT MatriXX give congruent pass/fail re-
sults with gamma criteria of 3%/3 mm. The I’mRT MatriXX Evolution array detector is not 
the most suitable option for stereotactic measurements, mainly due to the sparse spatial 
resolution, but it can be utilized to separate the unacceptable treatment plans from ac-
ceptable ones with coarse gamma criterion of 3%/3mm and pass/fail threshold of 95%. 
For portal dosimetry measurement with PDIP-algorithm, tighter gamma criteria can be 
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recommended, for example 3%/1mm with 90% pass/fail threshold. Utilization of portal 
dosimetry with AAA algorithm needs further studies, as no literature can be found at the 
moment. 
Results from the gamma analysis with different gamma analysis thresholds (5% or 60%) 
indicate the importance of the careful selection of gamma analysis threshold in the quality 
assurance protocol. In case of threshold of 60%, only the high dose region is taken into 
account in the analysis. In case of threshold of 5%, also the low dose region of the dis-
tribution is taken into account, but the noise is removed from the analysis. 
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7. CONCLUSIONS 
This thesis gives quantitative information of Varian portal dosimetry and IBA I’mRT Ma-
triXX Evolution –array detector, and how different variables affect the measurement re-
sults with these detectors. As a conclusion, the QA results of stereotactic treatment plans 
are dependent on measurement system, radiation beam energy, target volume, and 
analysis parameters such as threshold.  
Measurement results obtained with different measurement methods cannot be com-
pared directly. Different measurement systems can be used for different treatment plan 
types. Analysis parameters, such as gamma analysis threshold, gamma analysis criteria 
and gamma pass/fail threshold are required to be determined in the QA protocol sepa-
rately to each measurement device, to guarantee the comparability of measurement re-
sults. 
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APPENDIX A 
An example of a typical stereotactic treatment plan setting for a brain tumor
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APPENDIX B  
An example of a typical stereotactic treatment plan setting for a lung tumor
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APPENDIX C  
An example of a typical stereotactic treatment plan setting for a prostate tumor
 
